Skip to main content

Advertisement

Log in

Inhibition and induction of human cytochrome P450 enzymes: current status

  • Review Article
  • Published:
Archives of Toxicology Aims and scope Submit manuscript

Abstract

Variability of drug metabolism, especially that of the most important phase I enzymes or cytochrome P450 (CYP) enzymes, is an important complicating factor in many areas of pharmacology and toxicology, in drug development, preclinical toxicity studies, clinical trials, drug therapy, environmental exposures and risk assessment. These frequently enormous consequences in mind, predictive and pre-emptying measures have been a top priority in both pharmacology and toxicology. This means the development of predictive in vitro approaches. The sound prediction is always based on the firm background of basic research on the phenomena of inhibition and induction and their underlying mechanisms; consequently the description of these aspects is the purpose of this review. We cover both inhibition and induction of CYP enzymes, always keeping in mind the basic mechanisms on which to build predictive and preventive in vitro approaches. Just because validation is an essential part of any in vitro–in vivo extrapolation scenario, we cover also necessary in vivo research and findings in order to provide a proper view to justify in vitro approaches and observations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Abdel-Rahman SM, Marcucci K, Boge T et al (1999) Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine. Drug Metab Dispos 27:770–775

    PubMed  CAS  Google Scholar 

  • Abelö A, Andersson TB, Antonsson M et al (2000) Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 28:966–972

    PubMed  Google Scholar 

  • Agarwal S, Holton KL, Lanza R (2008) Efficient differentiation of functional hepatocytes from human embryonic stem cells. Stem Cells. doi:10.1634/stemcells.2007-1102

  • Aithal GP, Day CP, Kesteven PJ et al (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 27:717–719

    Article  Google Scholar 

  • Allqvist A, Miura J, Bertilsson L et al (2007) Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers. Eur J Clin Pharmacol 63:173–179

    Article  PubMed  CAS  Google Scholar 

  • Amet Y, Berthou F, Baird S et al (1995) Validation of the (omega-1)-hydroxylation of lauric acid as an in vitro substrate probe for human liver CYP2E1. Biochem Pharmacol 50:1775–1782

    Article  PubMed  CAS  Google Scholar 

  • Andersson T, Miners JO, Veronese ME et al (1993) Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 36:521–530

    PubMed  CAS  Google Scholar 

  • Andersson T, Miners JO, Veronese ME et al (1994) Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 38:131–137

    PubMed  CAS  Google Scholar 

  • Anglicheau D, Flamant M, Schlageter MH et al (2003) Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 18:2409–2414

    Article  PubMed  CAS  Google Scholar 

  • Aninat C, Piton A, Glaise D et al (2006) Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 34:75–83

    Article  PubMed  CAS  Google Scholar 

  • Antoniou T, Tseng AL (2005) Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 44:111–145

    Article  PubMed  CAS  Google Scholar 

  • Aoyama T, Yamano S, Guzelian PS et al (1990) Five of 12 forms of vaccinia virus-expressed human hepatic cytochrome P450 metabolically activate aflatoxin B1. Proc Natl Acad Sci USA 87:4790–4793

    Article  PubMed  CAS  Google Scholar 

  • Arpiainen S, Raffalli-Mathieu F, Lang MA et al (2005) Regulation of the Cyp2a5 gene involves an aryl hydrocarbon receptor-dependent pathway. Mol Pharmacol 67:1325–1333

    Article  PubMed  CAS  Google Scholar 

  • Arulmozhiraja S, Morita M (2004) Structure-activity relationships for the toxicity of polychlorinated dibenzofurans: approach through density functional theory-based descriptors. Chem Res Toxicol 17:348–356

    Article  PubMed  CAS  Google Scholar 

  • Asimus S, Elsherbiny D, Hai TN et al (2007) Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects. Fundam Clin Pharmacol 21:307–316

    Article  PubMed  CAS  Google Scholar 

  • Asimus S, Hai TN, Van Huong N et al (2008) Artemisinin and CYP2A6 activity in healthy subjects. Eur J Clin Pharmacol 64:283–292

    Article  PubMed  CAS  Google Scholar 

  • Attar M, Dong D, Ling KH et al (2003) Cytochrome P450 2C8 and flavin-containing monooxygenases are involved in the metabolism of tazarotenic acid in humans. Drug Metab Dispos 31:476–481

    Article  PubMed  CAS  Google Scholar 

  • Azuma H, Paulk N, Ranade A et al (2007) Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol 25:903–910

    Article  PubMed  CAS  Google Scholar 

  • Bäärnhielm C, Backman A, Hoffmann KJ et al (1986) Biotransformation of felodipine in liver microsomes from rat, dog, and man. Drug Metab Dispos 14:613–618

    PubMed  Google Scholar 

  • Bachmann K, White D, Jauregui L et al (2003) An evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probe. J Clin Pharmacol 43:1082–1090

    Article  PubMed  CAS  Google Scholar 

  • Back DJ, Houlgrave R, Tjia JF et al (1991) Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes. J Steroid Biochem Mol Biol 38:219–225

    Article  PubMed  CAS  Google Scholar 

  • Back DJ, Tjia JF, Karbwang J et al (1988) In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br J Clin Pharmacol 26:23–29

    PubMed  CAS  Google Scholar 

  • Back DJ, Tjia JF (1991) Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 32:624–626

    PubMed  CAS  Google Scholar 

  • Backman JT, Olkkola KT, Neuvonen PJ (1996) Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 59:7–13

    Article  PubMed  CAS  Google Scholar 

  • Backman JT, Granfors MT, Neuvonen PJ (2006a) Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. Eur J Clin Pharmacol 62:451–461

    Article  PubMed  CAS  Google Scholar 

  • Backman JT, Karjalainen MJ, Neuvonen M et al (2006b) Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. Br J Clin Pharmacol 62:345–357

    Article  PubMed  CAS  Google Scholar 

  • Balbisi EA (2006) Frovatriptan: a review of pharmacology, pharmacokinetics and clinical potential in the treatment of menstrual migraine. Ther Clin Risk Manag 2:303–308

    Article  PubMed  CAS  Google Scholar 

  • Baldwin SJ, Bloomer JC, Smith GJ et al (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261–270

    PubMed  CAS  Google Scholar 

  • Baldwin SJ, Clarke SE, Chenery RJ (1999) Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 48:424–432

    Article  PubMed  CAS  Google Scholar 

  • Barditch-Crovo P, Trapnell CB, Ette E et al (1999) The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. Clin Pharmacol Ther 65:428–438

    Article  PubMed  CAS  Google Scholar 

  • Becquemont L, Le Bot MA, Riche C et al (1998) Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine–fluvoxamine drug interaction in man. Pharmacogenetics 8:101–108

    Article  PubMed  CAS  Google Scholar 

  • Behnisch PA, Hosoe K, Sakai S (2001) Bioanalytical screening methods for dioxins and dioxin-like compounds a review of bioassay/biomarker technology. Environ Int 27:413–439

    Article  PubMed  CAS  Google Scholar 

  • Benowitz NL, Peng M, Jacob P 3rd (2003) Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. Clin Pharmacol Ther 74:468–474

    Article  PubMed  CAS  Google Scholar 

  • Benowitz NL, Lessov-Schlaggar CN, Swan GE et al (2006) Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther 79:480–488

    Article  PubMed  CAS  Google Scholar 

  • Berlin I, Gasior MJ, Moolchan ET (2007) Sex-based and hormonal contraception effects on the metabolism of nicotine among adolescent tobacco-dependent smokers. Nicotine Tob Res 9:493–498

    Article  PubMed  CAS  Google Scholar 

  • Bertilsson G, Heidrich J, Svensson K et al (1998) Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 95:12208–12213

    Article  PubMed  CAS  Google Scholar 

  • Bertilsson L, Carrillo JA, Dahl ML et al (1994) Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 38:471–473

    PubMed  CAS  Google Scholar 

  • Bertilsson L (1995) Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 29:192–209

    PubMed  CAS  Google Scholar 

  • Bidstrup TB, Bjørnsdottir I, Sidelmann UG et al (2003) CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol 56:305–314

    Article  PubMed  CAS  Google Scholar 

  • Bidstrup TB, Stilling N, Damkier P et al (2004) Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur J Clin Pharmacol 60:109–114

    Article  PubMed  CAS  Google Scholar 

  • Birkett DJ, Miners JO, Attwood J (1983) Evidence for a dual action of sulphinpyrazone on drug metabolism in man: theophylline-sulphinpyrazone interaction. Br J Clin Pharmacol 15:567–569

    PubMed  CAS  Google Scholar 

  • Birkett DJ, Rees D, Andersson T et al (1994) In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. Br J Clin Pharmacol 37:413–420

    PubMed  CAS  Google Scholar 

  • Bjeldanes LF, Kim JY, Grose KR et al (1991) Aromatic hydrocarbon responsiveness-receptor agonists generated from indole-3-carbinol in vitro and in vivo: comparisons with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Proc Natl Acad Sci USA 88:9543–9547

    Article  PubMed  CAS  Google Scholar 

  • Bjornsson TD, Callaghan JT, Einolf HJ et al (2003) The conduct of in vitro and in vivo drug–drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815–832

    Article  PubMed  CAS  Google Scholar 

  • Bloomer JC, Clarke SE, Chenery RJ (1997) In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole. Drug Metab Dispos 25:840–844

    PubMed  CAS  Google Scholar 

  • Blumberg B, Sabbagh W Jr, Juguilon H et al (1998) SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 12:3195–3205

    Article  PubMed  CAS  Google Scholar 

  • Bodin K, Bretillon L, Aden Y et al (2001) Antiepileptic drugs increase plasma levels of 4β-hydroxycholesterol in humans: evidence for involvement of cytochrome P450 3A4. J Biol Chem 276:38685–38689

    Article  PubMed  CAS  Google Scholar 

  • Bodin K, Lindbom U, Diczfalusy U (2005) Novel pathways of bile acid metabolism involving CYP3A4. Biochim Biophys Acta 1687:84–93

    PubMed  CAS  Google Scholar 

  • Boobis AR, Murray S, Kahn GC et al (1983) Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man. Mol Pharmacol 23:474–481

    PubMed  CAS  Google Scholar 

  • Boobis AR, Lynch AM, Murray S et al (1994) CYP1A2-catalyzed conversion of dietary heterocyclic amines to their proximate carcinogens is their major route of metabolism in humans. Cancer Res 54:89–94

    PubMed  CAS  Google Scholar 

  • Bourrié M, Meunier V, Berger Y et al (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321–332

    PubMed  Google Scholar 

  • Brady JF, Xiao F, Wang MH et al (1991a) Effects of disulfiram on hepatic P450IIE1, other microsomal enzymes, and hepatotoxicity in rats. Toxicol Appl Pharmacol 108:366–373

    Article  PubMed  CAS  Google Scholar 

  • Brady JF, Ishizaki H, Fukuto JM et al (1991b) Inhibition of cytochrome P-450 2E1 by diallyl sulfide and its metabolites. Chem Res Toxicol 4:642–647

    Article  PubMed  CAS  Google Scholar 

  • Broly F, Libersa C, Lhermitte M et al (1989) Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. Br J Clin Pharmacol 28:29–36

    PubMed  CAS  Google Scholar 

  • Brosen K, Skjelbo E, Rasmussen BB et al (1993) Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45:1211–1214

    Article  PubMed  CAS  Google Scholar 

  • Brown CM, Reisfeld B, Mayeno AN (2008) Cytochromes P450: a structure-based summary of biotransformations using representative substrates. Drug Metab Rev 40:1–100

    Article  PubMed  CAS  Google Scholar 

  • Buchan P, Wade A, Ward C et al (2002) Frovatriptan: a review of drug–drug interactions. Headache 42(suppl 2):S63–S73

    Article  PubMed  Google Scholar 

  • Buchthal J, Grund KE, Buchmann A et al (1995) Induction of cytochrome P4501A by smoking or omeprazole in comparison with UDP-glucuronosyltransferase in biopsies of human duodenal mucosa. Eur J Clin Pharmacol 47:431–435

    Article  PubMed  CAS  Google Scholar 

  • Burk O, Koch I, Raucy J et al (2004) The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem 279:38379–38385

    Article  PubMed  CAS  Google Scholar 

  • Burk O, Wojnowski L (2004) Cytochrome P450 3A and their regulation. Naunyn Schmiedebergs Arch Pharmacol 369:105–124

    Article  PubMed  CAS  Google Scholar 

  • Burke MD, Thompson S, Elcombe CR et al (1985) Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450. Biochem Pharmacol 34:3337–3345

    Article  PubMed  CAS  Google Scholar 

  • Busi F, Cresteil T (2005) CYP3A5 mRNA degradation by nonsense-mediated mRNA decay. Mol Pharmacol 68:808–815

    PubMed  CAS  Google Scholar 

  • Butler MA, Iwasaki M, Guengerich FP et al (1989) Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 86:7696–7700

    Article  PubMed  CAS  Google Scholar 

  • Cai J, Zhao Y, Liu Y et al (2007) Directed differentiation of human embryonic stem cells into functional hepatic cells. Hepatology 45:1229–1239

    Article  PubMed  CAS  Google Scholar 

  • Campard D, Lysy PA, Najimi M et al (2008) Native umbilical cord matrix stem cells express hepatic markers and differentiate into hepatocyte-like cells. Gastroenterology 134:833–848

    Article  PubMed  CAS  Google Scholar 

  • Campbell ME, Grant DM, Inaba T et al (1987) Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos 15:237–249

    PubMed  CAS  Google Scholar 

  • Carlile DJ, Hakooz N, Bayliss MK et al (1999) Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br J Clin Pharmacol 47:625–635

    Article  PubMed  CAS  Google Scholar 

  • Carlson DB, Perdew GH (2002) A dynamic role for the Ah receptor in cell signaling? Insights from a diverse group of Ah receptor interacting proteins. J Biochem Mol Toxicol 16:317–325

    Article  PubMed  CAS  Google Scholar 

  • Caro AA, Cederbaum AI (2004) Oxidative stress, toxicology, and pharmacology of CYP2E1. Annu Rev Pharmacol Toxicol 44:27–42

    Article  PubMed  CAS  Google Scholar 

  • Carroccio A, Wu D, Cederbaum AI (1994) Ethanol increases content and activity of human cytochrome P4502E1 in a transduced HepG2 cell line. Biochem Biophys Res Commun 203:727–733

    Article  PubMed  CAS  Google Scholar 

  • Cashman JR, Park SB, Yang ZC et al (1992) Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N′-oxide. Chem Res Toxicol 5:639–646

    Article  PubMed  CAS  Google Scholar 

  • Cederbaum AI (2006) CYP2E1—biochemical and toxicological aspects and role in alcohol-induced liver injury. Mt Sinai J Med 73:657–672

    PubMed  Google Scholar 

  • Chang SM, Kuhn JG, Rizzo J et al (1998) Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 16:2188–2194

    PubMed  CAS  Google Scholar 

  • Chang TK, Gonzalez FJ, Waxman DJ (1994) Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 311:437–442

    Article  PubMed  CAS  Google Scholar 

  • Chang TK, Chen J, Pillay V et al (2003) Real-time polymerase chain reaction analysis of CYP1B1 gene expression in human liver. Toxicol Sci 71:11–19

    Article  PubMed  CAS  Google Scholar 

  • Chang TK, Waxman DJ (2006) Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Drug Metab Rev 38:51–73

    Article  PubMed  CAS  Google Scholar 

  • Cheng YW, Chen CY, Lin P et al (2000) DNA adduct level in lung tissue may act as a risk biomarker of lung cancer. Eur J Cancer 36:1381–1388

    Article  PubMed  CAS  Google Scholar 

  • Chiba K, Kobayashi K, Manabe K et al (1993) Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation. J Pharmacol Exp Ther 266:52–59

    PubMed  CAS  Google Scholar 

  • Chiba M, Hensleigh M, Nishime JA et al (1996) Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 24:307–314

    PubMed  CAS  Google Scholar 

  • Chien JY, Peter RM, Nolan CM et al (1997) Influence of polymorphic N-acetyltransferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazid. Clin Pharmacol Ther 61:24–34

    Article  PubMed  CAS  Google Scholar 

  • Chou CH, Evans AM, Fornasini G et al (1993) Relationship between lipophilicity and hepatic dispersion and distribution for a homologous series of barbiturates in the isolated perfused in situ rat liver. Drug Metab Dispos 21:933–938

    PubMed  CAS  Google Scholar 

  • Christian K, Lang M, Maurel P et al (2004) Interaction of heterogeneous nuclear ribonucleoprotein A1 with cytochrome P450 2A6 mRNA: implications for post-transcriptional regulation of the CYP2A6 gene. Mol Pharmacol 65:1405–1414

    Article  PubMed  CAS  Google Scholar 

  • Christians U, Strohmeyer S, Kownatzki R et al (1991) Investigations on the metabolic pathways of cyclosporine: II. Elucidation of the metabolic pathways in vitro by human liver microsomes. Xenobiotica 21:1199–1210

    PubMed  CAS  Google Scholar 

  • Clarke SE, Ayrton AD, Chenery RJ (1994a) Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica 24:517–526

    PubMed  CAS  Google Scholar 

  • Clarke SE, Baldwin SJ, Bloomer JC et al (1994b) Lauric acid as a model substrate for the simultaneous determination of cytochrome P450 2E1 and 4A in hepatic microsomes. Chem Res Toxicol 7:836–842

    Article  PubMed  CAS  Google Scholar 

  • Code EL, Crespi CL, Penman BW et al (1997) Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos 25:985–993

    PubMed  CAS  Google Scholar 

  • Coller JK, Somogyi AA, Bochner F (1999) Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms. Br J Clin Pharmacol 48:158–167

    Article  PubMed  CAS  Google Scholar 

  • Cook CS, Berry LM, Burton E (2004) Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data. Xenobiotica 34:215–228

    Article  PubMed  CAS  Google Scholar 

  • Court MH, Duan SX, Hesse LM et al (2001) Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology 94:110–119

    Article  PubMed  CAS  Google Scholar 

  • Cresteil T, Monsarrat B, Alvinerie P et al (1994) Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 54:386–392

    PubMed  CAS  Google Scholar 

  • Crewe HK, Lennard MS, Tucker GT et al (1992) The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 34:262–265

    PubMed  CAS  Google Scholar 

  • Cvetkovic M, Leake B, Fromm MF et al (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866–871

    PubMed  CAS  Google Scholar 

  • Dahl ML (2002) Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 41:453–470

    Article  PubMed  CAS  Google Scholar 

  • Dahlqvist R, Steiner E, Koike Y et al (1989) Induction of theophylline metabolism by pentobarbital. Ther Drug Monit 11:408–410

    PubMed  CAS  Google Scholar 

  • Dai D, Zeldin DC, Blaisdell JA et al (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597–607

    Article  PubMed  CAS  Google Scholar 

  • Dai Y, Hebert MF, Isoherranen N et al (2006) Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 34:836–847

    Article  PubMed  CAS  Google Scholar 

  • Dailly E, Tribut O, Tattevin P et al (2006) Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. Eur J Clin Pharmacol 62:523–526

    Article  PubMed  CAS  Google Scholar 

  • Daly AK, King BP (2003) Pharmacogenetics of oral anticoagulants. Pharmacogenetics 13:247–252

    Article  PubMed  CAS  Google Scholar 

  • Darwish M, Kirby M, Robertson P Jr et al (2008) Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet 47:61–74

    PubMed  CAS  Google Scholar 

  • Dayer P, Desmeules J, Leemann T et al (1988) Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochem Biophys Res Commun 152:411–416

    Article  PubMed  CAS  Google Scholar 

  • de Wildt SN, Kearns GL, Leeder JS, van den Anker JN (1999) Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 37:485–505

    Article  PubMed  Google Scholar 

  • Dempsey D, Jacob P 3rd, Benowitz NL (2002) Accelerated metabolism of nicotine and cotinine in pregnant smokers. J Pharmacol Exp Ther 301:594–598

    Article  PubMed  CAS  Google Scholar 

  • Dennison JB, Kulanthaivel P, Barbuch RJ et al (2006) Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 34:1317–1327

    Article  PubMed  CAS  Google Scholar 

  • Depre M, Van Hecken A, Oeyen M et al (2005) Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol 61:341–346

    Article  PubMed  CAS  Google Scholar 

  • Desai PB, Duan JZ, Zhu YW et al (1998) Human liver microsomal metabolism of paclitaxel and drug interactions. Eur J Drug Metab Pharmacokinet 23:417–424

    PubMed  CAS  Google Scholar 

  • Desta Z, Zhao X, Shin JG et al (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41:913–958

    Article  PubMed  CAS  Google Scholar 

  • Desta Z, Saussele T, Ward B et al (2007) Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 8:547–558

    Article  PubMed  CAS  Google Scholar 

  • Dickinson RG, Hooper WD, Patterson M et al (1985) Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin. Ther Drug Monit 7:283–289

    Article  PubMed  CAS  Google Scholar 

  • Diczfalusy U, Miura J, Roh HK et al (2008) 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics 18:201–208

    Article  PubMed  CAS  Google Scholar 

  • Ding X, Kaminsky LS (2003) Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43:149–173

    Article  PubMed  CAS  Google Scholar 

  • Dingemanse J, van Giersbergen PL (2004) Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 43:1089–1115

    Article  PubMed  CAS  Google Scholar 

  • Distlerath LM, Reilly PE, Martin MV et al (1985) Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 260:9057–9067

    PubMed  CAS  Google Scholar 

  • Djordjevic N, Ghotbi R, Bertilsson L et al (2008) Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. Eur J Clin Pharmacol 64:381–385

    Article  PubMed  CAS  Google Scholar 

  • Doecke CJ, Veronese ME, Pond SM et al (1991) Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol 31:125–130

    PubMed  CAS  Google Scholar 

  • Dolwick KM, Schmidt JV, Carver LA et al (1993) Cloning and expression of a human Ah receptor cDNA. Mol Pharmacol 44:911–917

    PubMed  CAS  Google Scholar 

  • Donato MT, Viitala P, Rodriguez-Antona C et al (2000) CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers. Drug Metab Dispos 28:1321–1326

    PubMed  CAS  Google Scholar 

  • Donato MT, Lahoz A, Castell JV et al (2008) Cell lines: a tool for in vitro drug metabolism studies. Curr Drug Metab 9:1–11

    Article  PubMed  CAS  Google Scholar 

  • Draper AJ, Madan A, Parkinson A (1997) Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch Biochem Biophys 341:47–61

    Article  PubMed  CAS  Google Scholar 

  • Dresser GK, Bailey DG, Leake BF et al (2002) Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71:11–20

    Article  PubMed  CAS  Google Scholar 

  • Eagling VA, Back DJ, Barry MG (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44:190–194

    Article  PubMed  CAS  Google Scholar 

  • Edwards RJ, Price RJ, Watts PS et al (2003) Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 31:282–288

    Article  PubMed  CAS  Google Scholar 

  • Eichelbaum M, Ingelman-Sundberg M, Evans WE (2006) Pharmacogenomics and individualized drug therapy. Annu Rev Med 57:119–137

    Article  PubMed  CAS  Google Scholar 

  • Ek M, Söderdahl T, Küppers-Munther B et al (2007) Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. Biochem Pharmacol 74:496–503

    Article  PubMed  CAS  Google Scholar 

  • Ekins S, Erickson JA (2002) A pharmacophore for human pregnane X receptor ligands. Drug Metab Dispos 30:96–99

    Article  PubMed  CAS  Google Scholar 

  • Ekins S, Mirny L, Schuetz EG (2002) A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha, and LXRbeta. Pharm Res 19:1788–1800

    Article  PubMed  CAS  Google Scholar 

  • Ekins S, Stresser DM, Williams JA (2003) In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol Sci 24:161–166

    Article  PubMed  CAS  Google Scholar 

  • Ekins S, Andreyev S, Ryabov A et al (2006) A combined approach to drug metabolism and toxicity assessment. Drug Metab Dispos 34:495–503

    PubMed  CAS  Google Scholar 

  • Ekins S, Chang C, Mani S et al (2007) Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol Pharmacol 72:592–603

    Article  PubMed  CAS  Google Scholar 

  • Ekström G, Gunnarsson UB (1996) Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes. Drug Metab Dispos 24:955–961

    PubMed  Google Scholar 

  • Elkayam T, Amitay-Shaprut S, Dvir-Ginzberg M et al (2006) Enhancing the drug metabolism activities of C3A—a human hepatocyte cell line—by tissue engineering within alginate scaffolds. Tissue Eng 12:1357–1368

    Article  PubMed  CAS  Google Scholar 

  • El-Sankary W, Gibson GG, Ayrton A et al (2001) Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab Dispos 29:1499–1504

    PubMed  CAS  Google Scholar 

  • Elsherbiny DA, Asimus SA, Karlsson MO et al (2008) A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens. J Pharmacokinet Pharmacodyn. doi:10.1007/s10928-008-9084-6

  • Emoto C, Yamato Y, Sato Y et al (2008) Non-invasive method to detect induction of CYP3A4 in chimeric mice with a humanized liver. Xenobiotica 38:239–248

    Article  PubMed  CAS  Google Scholar 

  • Endo T, Ban M, Hirata K et al (2007) Involvement of CYP2A6 in the formation of a novel metabolite, 3-hydroxypilocarpine, from pilocarpine in human liver microsomes. Drug Metab Dispos 35:476–483

    Article  PubMed  CAS  Google Scholar 

  • Eriksson UG, Lundahl J, Bäärnhielm C et al (1991) Stereoselective metabolism of felodipine in liver microsomes from rat, dog, and human. Drug Metab Dispos 19:889–894

    PubMed  CAS  Google Scholar 

  • Ernest CS 2nd, Hall SD, Jones DR (2005) Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 312:583–591

    Article  PubMed  CAS  Google Scholar 

  • Evans DC, O’Connor D, Lake BG et al (2003) Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos 31:861–869

    Article  PubMed  CAS  Google Scholar 

  • Faber MS, Jetter A, Fuhr U (2005) Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 97:125–134

    Article  PubMed  CAS  Google Scholar 

  • Facciolá G, Hidestrand M, von Bahr C et al (2001) Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. Eur J Clin Pharmacol 56:881–888

    Article  PubMed  Google Scholar 

  • Fang J, Coutts RT, McKenna KF et al (1998) Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch Pharmacol 358:592–599

    Article  PubMed  CAS  Google Scholar 

  • Faucette SR, Hawke RL, Lecluyse EL et al (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222–1230

    PubMed  CAS  Google Scholar 

  • Faucette SR, Zhang TC, Moore R et al (2007) Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 320:72–80

    Article  PubMed  CAS  Google Scholar 

  • Fellay J, Marzolini C, Decosterd L et al (2005) Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur J Clin Pharmacol 60:865–873

    Article  PubMed  CAS  Google Scholar 

  • Fetell MR, Grossman SA, Fisher JD et al (1997) Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New approaches to brain tumor therapy central nervous system consortium. J Clin Oncol 15:3121–3128

    PubMed  CAS  Google Scholar 

  • Fontana RJ, Lown KS, Paine MF et al (1999) Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. Gastroenterology 117:89–98

    Article  PubMed  CAS  Google Scholar 

  • Forman BM, Tzameli I, Choi HS et al (1998) Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. Nature 395:612–615

    Article  PubMed  CAS  Google Scholar 

  • Frank C, Molnár F, Matilainen M et al (2004) Agonist-dependent and agonist-independent transactivations of the human constitutive androstane receptor are modulated by specific amino acid pairs. J Biol Chem 279:33558–33566

    Article  PubMed  CAS  Google Scholar 

  • Friedman MA, Woodcock J, Lumpkin MM et al (1999) The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA 281:1728–1734

    Article  PubMed  CAS  Google Scholar 

  • Fuhr U, Wolff T, Harder S et al (1990) Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes. Drug Metab Dispos 18:1005–1010

    PubMed  CAS  Google Scholar 

  • Fujita K (2004) Food–drug interactions via human cytochrome P450 3A (CYP3A). Drug Metabol Drug Interact 20:195–217

    PubMed  CAS  Google Scholar 

  • Fukuda I, Nishiumi S, Yabushita Y et al (2004) A new southwestern chemistry-based ELISA for detection of aryl hydrocarbon receptor transformation: application to the screening of its receptor agonists and antagonists. J Immunol Methods 287:187–201

    Article  PubMed  CAS  Google Scholar 

  • Funck-Brentano C, Becquemont L, Lenevu A et al (1997) Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. J Pharmacol Exp Ther 280:730–738

    PubMed  CAS  Google Scholar 

  • Furster C, Wikvall K (1999) Identification of CYP3A4 as the major enzyme responsible for 25-hydroxylation of 5β-cholestane-3α, 7α, 12α-triol in human liver microsomes. Biochim Biophys Acta 1437:46–52

    PubMed  CAS  Google Scholar 

  • Galetin A, Clarke SE, Houston JB (2003) Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine. Drug Metab Dispos 31:1108–1116

    Article  PubMed  CAS  Google Scholar 

  • Galetin A, Burt H, Gibbons L et al (2006) Prediction of time-dependent CYP3A4 drug–drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 34:166–175

    Article  PubMed  CAS  Google Scholar 

  • Galteau MM, Shamsa F (2003) Urinary 6β-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol 59:713–733

    Article  PubMed  CAS  Google Scholar 

  • Garcia M, Rager J, Wang Q et al (2003) Cryopreserved human hepatocytes as alternative in vitro model for cytochrome P450 induction studies. In Vitro Cell Dev Biol Anim 39:283–287

    Article  PubMed  CAS  Google Scholar 

  • Gebhardt AC, Lucas D, Ménez JF et al (1997) Chlormethiazole inhibition of cytochrome P450 2E1 as assessed by chlorzoxazone hydroxylation in humans. Hepatology 26:957–961

    Article  PubMed  CAS  Google Scholar 

  • Ghanbari F, Rowland-Yeo K, Bloomer JC et al (2006) A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro–in vivo extrapolation. Curr Drug Metab 7:315–334

    Article  PubMed  CAS  Google Scholar 

  • Giancarlo GM, Venkatakrishnan K, Granda BW et al (2001) Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. Eur J Clin Pharmacol 57:31–36

    Article  PubMed  CAS  Google Scholar 

  • Girre C, Lucas D, Hispard E et al (1994) Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem Pharmacol 47:1503–1508

    Article  PubMed  CAS  Google Scholar 

  • Glaeser H, Drescher S, Eichelbaum M et al (2005) Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes. Br J Clin Pharmacol 59:199–206

    Article  PubMed  CAS  Google Scholar 

  • Goldberg MR, Lo MW, Deutsch PJ et al (1996) Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174. Clin Pharmacol Ther 59:268–274

    Article  PubMed  CAS  Google Scholar 

  • Gómez-Lechón MJ, Donato T, Jover R et al (2001) Expression and induction of a large set of drug-metabolizing enzymes by the highly differentiated human hepatoma cell line BC2. Eur J Biochem 268(5):1448–1459

    Article  PubMed  Google Scholar 

  • Gómez-Lechón MJ, Donato MT, Castell JV et al (2003) Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr Drug Metab 4:292–312

    Article  PubMed  Google Scholar 

  • Gonzalez FJ (2005) Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutat Res 569:101–110

    PubMed  CAS  Google Scholar 

  • Goodwin B, Hodgson E, Liddle C (1999) The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 56:1329–1339

    PubMed  CAS  Google Scholar 

  • Goodwin B, Moore LB, Stoltz CM et al (2001) Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 60:427–431

    PubMed  CAS  Google Scholar 

  • Gorski JC, Jones DR, Hamman MA et al (1999) Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily. Xenobiotica 29:931–944

    Article  PubMed  CAS  Google Scholar 

  • Granfors MT, Backman JT, Laitila J et al (2004) Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. Br J Clin Pharmacol 57:349–353

    Article  PubMed  CAS  Google Scholar 

  • Gripon P, Rumin S, Urban S et al (2002) Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 99:15655–15660

    Article  PubMed  CAS  Google Scholar 

  • Gu CG, Jiang X, Ju XH et al (2007) DFT study on the structure-toxicity relationship of dioxin compounds using PLS analysis. SAR QSAR Environ Res 18:603–619

    Article  PubMed  CAS  Google Scholar 

  • Guengerich FP, Müller-Enoch D, Blair IA (1986) Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 30:287–295

    PubMed  CAS  Google Scholar 

  • Guengerich FP (1990) Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol 3:363–371

    Article  PubMed  CAS  Google Scholar 

  • Guengerich FP, Kim DH, Iwasaki M (1991) Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 4:168–179

    Article  PubMed  CAS  Google Scholar 

  • Guengerich FP, Wu Z, Bartleson CJ (2005) Function of human cytochrome P450s: characterisation of the orphans. Biochem Biophys Res Commun 338:465–469

    Article  PubMed  CAS  Google Scholar 

  • Guengerich FP (2008) Cytochrome p450 and chemical toxicology. Chem Res Toxicol 21:70–83

    Article  PubMed  CAS  Google Scholar 

  • Gurley BJ, Gardner SF, Hubbard MA et al (2002) Cytochrome P450 phenotypic ratios for predicting herb–drug interactions in humans. Clin Pharmacol Ther 72:276–287

    Article  PubMed  CAS  Google Scholar 

  • Gurley BJ, Gardner SF, Hubbard MA et al (2005) Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John’s wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 22:525–539

    Article  PubMed  CAS  Google Scholar 

  • Ha-Duong NT, Dijols S, Macherey AC et al (2001) Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 40:12112–12122

    Article  PubMed  CAS  Google Scholar 

  • Hakkola J, Pelkonen O, Pasanen M et al (1998) Xenobiotic-metabolizing cytochrome P450 enzymes in the human feto-placental unit: role in intrauterine toxicity. Crit Rev Toxicol 28:35–72

    Article  PubMed  CAS  Google Scholar 

  • Hakkola J, Raunio H, Purkunen R et al (2001) Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers. Biol Neonate 80:193–201

    Article  PubMed  CAS  Google Scholar 

  • Hall SD, Thummel KE, Watkins PB et al (1999) Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 27:161–166

    PubMed  CAS  Google Scholar 

  • Halpert JR (1995) Structural basis of selective cytochrome P450 inhibition. Annu Rev Pharmacol Toxicol 35:29–53

    Article  PubMed  CAS  Google Scholar 

  • Hamman MA, Thompson GA, Hall SD (1997) Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol 54:33–41

    Article  PubMed  CAS  Google Scholar 

  • Hanaoka T, Yamano Y, Pan G et al (2002) Cytochrome P450 1B1 mRNA levels in peripheral blood cells and exposure to polycyclic aromatic hydrocarbons in Chinese coke oven workers. Sci Total Environ 296:27–33

    Article  PubMed  CAS  Google Scholar 

  • Hargreaves MB, Jones BC, Smith DA et al (1994) Inhibition of p-nitrophenol hydroxylase in rat liver microsomes by small aromatic and heterocyclic molecules. Drug Metab Dispos 22:806–810

    PubMed  CAS  Google Scholar 

  • Hariparsad N, Carr BA, Evers R et al (2008) Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction. Drug Metab Dispos. doi:10.1124/dmd.108.020677

  • Harleton E, Webster M, Bumpus NN et al (2004) Metabolism of N, N′, N″-triethylenethiophosphoramide by CYP2B1 and CYP2B6 results in the inactivation of both isoforms by two distinct mechanisms. J Pharmacol Exp Ther 310:1011–1019

    Article  PubMed  CAS  Google Scholar 

  • Hartley DP, Dai X, Yabut J et al (2006) Identification of potential pharmacological and toxicological targets differentiating structural analogs by a combination of transcriptional profiling and promoter analysis in LS-180 and Caco-2 adenocarcinoma cell lines. Pharmacogenet Genomics 16:579–599

    Article  PubMed  CAS  Google Scholar 

  • Härtter S, Wang X, Weigmann H et al (2001) Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J Clin Psychopharmacol 21:167–174

    Article  PubMed  Google Scholar 

  • He N, Edeki T (2004) The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am J Ther 11:206–212

    Article  PubMed  Google Scholar 

  • Hecht SS (1999) DNA adduct formation from tobacco-specific N-nitrosamines. Mutat Res 424:127–142

    PubMed  CAS  Google Scholar 

  • Heimark LD, Wienkers L, Kunze K et al (1992) The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther 51:398–407

    PubMed  CAS  Google Scholar 

  • Heinemeyer G, Gramm HJ, Simgen W et al (1987) Kinetics of hexobarbital and dipyrone in critical care patients receiving high-dose pentobarbital. Eur J Clin Pharmacol 32:273–277

    Article  PubMed  CAS  Google Scholar 

  • Hengstler JG, Utesch D, Steinberg P et al (2000) Cryopreserved primary hepatocytes as a constantly available in vitro model for the evaluation of human and animal drug metabolism and enzyme induction. Drug Metab Rev 32:81–118

    Article  PubMed  CAS  Google Scholar 

  • Herman D, Locatelli I, Grabnar I et al (2006) The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. Eur J Clin Pharmacol 62:291–296

    Article  PubMed  CAS  Google Scholar 

  • Hesse LM, Venkatakrishnan K, Court MH et al (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176–1183

    PubMed  CAS  Google Scholar 

  • Hewitt NJ, Hewitt P (2004) Phase I and II enzyme characterization of two sources of HepG2 cell lines. Xenobiotica 34:243–256

    Article  PubMed  CAS  Google Scholar 

  • Hewitt NJ, Lechón MJ, Houston JB et al (2007a) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159–234

    Article  PubMed  CAS  Google Scholar 

  • Hewitt NJ, de Kanter R, LeCluyse E (2007b) Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry—do they comply with FDA recommendations? Chem Biol Interact 168:51–65

    Article  PubMed  CAS  Google Scholar 

  • Hewitt NJ, Lecluyse EL, Ferguson SS (2007c) Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro–in vivo correlations. Xenobiotica 37:1196–1224

    Article  PubMed  CAS  Google Scholar 

  • Higashi E, Fukami T, Itoh M et al (2007a) Human CYP2A6 is induced by estrogen via estrogen receptor. Drug Metab Dispos 35:1935–1941

    Article  PubMed  CAS  Google Scholar 

  • Higashi E, Nakajima M, Katoh M et al (2007b) Inhibitory effects of neurotransmitters and steroids on human CYP2A6. Drug Metab Dispos 35:508–514

    Article  PubMed  CAS  Google Scholar 

  • Hijazi Y, Boulieu R (2002) Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 30:853–858

    Article  PubMed  CAS  Google Scholar 

  • Hines RN, McCarver DG (2002) The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 300:355–360

    Article  PubMed  CAS  Google Scholar 

  • Hollenberg PF (2002) Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metab Rev 34:17–35

    Article  PubMed  CAS  Google Scholar 

  • Honkakoski P, Negishi M (1997) Characterization of a phenobarbital-responsive enhancer module in mouse P450 Cyp2b10 gene. J Biol Chem 272:14943–14949

    Article  PubMed  CAS  Google Scholar 

  • Honkakoski P, Moore R, Washburn KA et al (1998a) Activation by diverse xenochemicals of the 51-base pair phenobarbital-responsive enhancer module in the CYP2B10 gene. Mol Pharmacol 53:597–601

    PubMed  CAS  Google Scholar 

  • Honkakoski P, Zelko I, Sueyoshi T et al (1998b) The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene. Mol Cell Biol 18:5652–5658

    PubMed  CAS  Google Scholar 

  • Hooper WD, Pool WF, Woolf TF et al (1994) Stereoselective hydroxylation of tacrine in rats and humans. Drug Metab Dispos 22:719–724

    PubMed  CAS  Google Scholar 

  • Houston JB, Galetin A (2005) Modelling atypical CYP3A4 kinetics: principles and pragmatism. Arch Biochem Biophys 433:351–360

    Article  PubMed  CAS  Google Scholar 

  • Howard LA, Miksys S, Hoffmann E et al (2003) Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics. Br J Pharmacol 138:1376–1386

    Article  PubMed  CAS  Google Scholar 

  • Hruska MW, Amico JA, Langaee TY et al (2005) The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. Br J Clin Pharmacol 59:70–79

    Article  PubMed  CAS  Google Scholar 

  • Hrycay EG, Bandiera SM (2008) Cytochrome P450 Enzymes. In: Gad SC (ed) Preclinical development handbook. ADME and biopharmaceutical properties. Wiley, New York

    Google Scholar 

  • Hsiang B, Zhu Y, Wang Z et al (1999) A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274:37161–37168

    Article  PubMed  CAS  Google Scholar 

  • Hsu A, Granneman GR, Bertz RJ (1998) Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 35:275–291

    Article  PubMed  CAS  Google Scholar 

  • Hu Y, Mishin V, Johansson I et al (1994) Chlormethiazole as an efficient inhibitor of cytochrome P450 2E1 expression in rat liver. J Pharmacol Exp Ther 269:1286–1291

    PubMed  CAS  Google Scholar 

  • Hu SW, Chen CC, Kuo CY et al (2006) Increased cytochrome P4501B1 gene expression in peripheral leukocytes of municipal waste incinerator workers. Toxicol Lett 160:112–120

    Article  PubMed  CAS  Google Scholar 

  • Huang Z, Roy P, Waxman DJ (2000) Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 59:961–972

    Article  PubMed  CAS  Google Scholar 

  • Huang W, Zhang J, Chua SS et al (2003) Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc Natl Acad Sci USA 100:4156–4161

    Article  PubMed  CAS  Google Scholar 

  • Huang SM, Temple R, Throckmorton DC et al (2007) Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 81:298–304

    Article  PubMed  CAS  Google Scholar 

  • Hukkanen J, Pelkonen O, Hakkola J et al (2002) Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit Rev Toxicol 32:391–411

    Article  PubMed  CAS  Google Scholar 

  • Hukkanen J, Väisänen T, Lassila A et al (2003) Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J Pharmacol Exp Ther 304:745–752

    Article  PubMed  CAS  Google Scholar 

  • Hukkanen J, Jacob P 3rd, Benowitz NL (2005) Metabolism and disposition kinetics of nicotine. Pharmacol Rev 57:79–115

    Article  PubMed  CAS  Google Scholar 

  • Huuskonen P, Storvik M, Reinisalo M et al (2008) Microarray analysis of the global alterations in the gene expression in the placentas from cigarette-smoking mothers. Clin Pharmacol Ther 83:542–550

    Article  PubMed  CAS  Google Scholar 

  • Hyland R, Roe EG, Jones BC, Smith DA (2001) Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol 51:239–248

    Article  PubMed  CAS  Google Scholar 

  • Iannone MA, Consler TG, Pearce KH et al (2001) Multiplexed molecular interactions of nuclear receptors using fluorescent microspheres. Cytometry 44:326–337

    Article  PubMed  CAS  Google Scholar 

  • Ingelman-Sundberg M (2005) The human genome project and novel aspects of cytochrome P450 research. Toxicol Appl Pharmacol 207(suppl 2):52–56

    Article  PubMed  CAS  Google Scholar 

  • Ingelman-Sundberg M, Sim SC, Gomez A et al (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496–526

    Article  PubMed  CAS  Google Scholar 

  • Ioannides C, Lewis DF (2004) Cytochromes P450 in the bioactivation of chemicals. Curr Top Med Chem 4:1767–1788

    Article  PubMed  CAS  Google Scholar 

  • Isoherranen N, Kunze KL, Allen KE et al (2004) Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 32:1121–1131

    Article  PubMed  CAS  Google Scholar 

  • Ito K, Iwatsubo T, Kanamitsu S et al (1998) Prediction of pharmacokinetic alterations caused by drug–drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387–412

    PubMed  CAS  Google Scholar 

  • Ito K, Ogihara K, Kanamitsu S et al (2003) Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 31:945–954

    Article  PubMed  CAS  Google Scholar 

  • Ito K, Brown HS, Houston JB (2004) Database analyses for the prediction of in vivo drug–drug interactions from in vitro data. Br J Clin Pharmacol 57:473–486

    Article  PubMed  CAS  Google Scholar 

  • Iwahori T, Matsuura T, Maehashi H et al (2003) CYP3A4 inducible model for in vitro analysis of human drug metabolism using a bioartificial liver. Hepatology 37:665–673

    Article  PubMed  CAS  Google Scholar 

  • Jaakkola T, Backman JT, Neuvonen M et al (2006a) Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone. Eur J Clin Pharmacol 62(7):503–509

    Article  PubMed  CAS  Google Scholar 

  • Jaakkola T, Backman JT, Neuvonen M et al (2006b) Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol 61:70–78

    Article  PubMed  CAS  Google Scholar 

  • Jacobs MN (2004) In silico tools to aid risk assessment of endocrine disrupting chemicals. Toxicology 205:43–53

    Article  PubMed  CAS  Google Scholar 

  • Jacobsen W, Kirchner G, Hallensleben K et al (1999) Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 27:173–179

    PubMed  CAS  Google Scholar 

  • Jacobsen W, Kuhn B, Soldner A et al (2000) Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos 28:1369–1378

    PubMed  CAS  Google Scholar 

  • Jao JY, Jusko WJ, Cohen JL (1972) Phenobarbital effects on cyclophosphamide pharmacokinetics in man. Cancer Res 32:2761–2764

    PubMed  CAS  Google Scholar 

  • Jiang X, Williams KM, Liauw WS et al (2004) Effect of St John’s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 57:592–599

    Article  PubMed  CAS  Google Scholar 

  • Jiang X, Blair EY, McLachlan AJ (2006) Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach. J Clin Pharmacol 46:1370–1378

    Article  PubMed  CAS  Google Scholar 

  • Jones SA, Moore LB, Shenk JL et al (2000) The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 14:27–39

    Article  PubMed  CAS  Google Scholar 

  • Josse R, Aninat C, Glaise D et al (2008) Long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies. Drug Metab Dispos. doi:10.1124/dmd.107.019901

  • Justesen US, Klitgaard NA, Brosen K et al (2003) Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers. Br J Clin Pharmacol 55:100–106

    Article  PubMed  CAS  Google Scholar 

  • Jyrkkärinne J, Mäkinen J, Gynther J et al (2003) Molecular determinants of steroid inhibition for the mouse constitutive androstane receptor. J Med Chem 46:4687–4695

    Article  PubMed  CAS  Google Scholar 

  • Jyrkkärinne J, Windshügel B, Mäkinen J et al (2005) Amino acids important for ligand specificity of the human constitutive androstane receptor. J Biol Chem 280:5960–5971

    Article  PubMed  CAS  Google Scholar 

  • Kahn GC, Boobis AR, Murray S et al (1982) Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver. Br J Clin Pharmacol 13:637–645

    PubMed  CAS  Google Scholar 

  • Kajosaari LI, Laitila J, Neuvonen PJ et al (2005) Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol 97:249–256

    Article  PubMed  CAS  Google Scholar 

  • Kamdem LK, Streit F, Zanger UM et al (2005) Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 51:1374–1381

    Article  PubMed  CAS  Google Scholar 

  • Kanebratt KP, Andersson TB (2008) HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos 36:137–145

    Article  PubMed  CAS  Google Scholar 

  • Kapitulnik J, Strobel HW (1999) Extrahepatic drug metabolizing enzymes. J Biochem Mol Toxicol 13:227–230

    Article  PubMed  CAS  Google Scholar 

  • Karjalainen MJ, Neuvonen PJ, Backman JT (2006) Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactions. Drug Metab Dispos 34:2091–2096

    Article  PubMed  CAS  Google Scholar 

  • Kashuba AD, Tierney C, Downey GF et al (2005) Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. Aids 19:145–152

    Article  PubMed  CAS  Google Scholar 

  • Katiyar SK, Matsui MS, Mukhtar H (2000) Ultraviolet-B exposure of human skin induces cytochromes P450 1A1 and 1B1. J Invest Dermatol 114:328–333

    Article  PubMed  CAS  Google Scholar 

  • Katoh M, Tateno C, Yoshizato K et al (2008) Chimeric mice with humanized liver. Toxicology 246:9–17

    Article  PubMed  CAS  Google Scholar 

  • Kawajiri K, Fujii-Kuriyama Y (2007) Cytochrome P450 gene regulation and physiological functions mediated by the aryl hydrocarbon receptor. Arch Biochem Biophys 464:207–212

    Article  PubMed  CAS  Google Scholar 

  • Kawana K, Ikuta T, Kobayashi Y et al (2003) Molecular mechanism of nuclear translocation of an orphan nuclear receptor, SXR. Mol Pharmacol 63:524–531

    Article  PubMed  CAS  Google Scholar 

  • Kay L, Kampmann JP, Svendsen TL et al (1985) Influence of rifampicin and isoniazid on the kinetics of phenytoin. Br J Clin Pharmacol 20:323–326

    PubMed  CAS  Google Scholar 

  • Kearney AS, Crawford LF, Mehta SC et al (1993) The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981. Pharm Res 10:1461–1465

    Article  PubMed  CAS  Google Scholar 

  • Kent UM, Juschyshyn MI, Hollenberg PF (2001) Mechanism-based inactivators as probes of cytochrome P450 structure and function. Curr Drug Metab 2:215–243

    Article  PubMed  CAS  Google Scholar 

  • Kent UM, Mills DE, Rajnarayanan RV et al (2002) Effect of 17-alpha-ethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites. J Pharmacol Exp Ther 300:549–558

    Article  PubMed  CAS  Google Scholar 

  • Kenworthy KE, Bloomer JC, Clarke SE et al (1999) CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716–727

    Article  PubMed  CAS  Google Scholar 

  • Kessova I, Cederbaum AI (2003) CYP2E1: biochemistry, toxicology, regulation and function in ethanol-induced liver injury. Curr Mol Med 3:509–518

    Article  PubMed  CAS  Google Scholar 

  • Ketter TA, Jenkins JB, Schroeder DH et al (1995) Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol 15:327–333

    Article  PubMed  CAS  Google Scholar 

  • Kharasch ED, Hankins DC, Baxter PJ et al (1998) Single-dose disulfiram does not inhibit CYP2A6 activity. Clin Pharmacol Ther 64:39–45

    Article  PubMed  CAS  Google Scholar 

  • Kharasch ED, Mitchell D, Coles R et al (2008) Rapid clinical induction of hepatic cytochrome P4502B6 (CYP2B6) activity by ritonavir. Antimicrob Agents Chemother. doi:10.1128/AAC.01600-07

  • Kim RB, Wandel C, Leake B et al (1999) Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 16:408–414

    Article  PubMed  CAS  Google Scholar 

  • Kim J, Min G, Kemper B (2001) Chromatin assembly enhances binding to the CYP2B1 phenobarbital-responsive unit (PBRU) of nuclear factor-1, which binds simultaneously with constitutive androstane receptor (CAR)/retinoid X receptor (RXR) and enhances CAR/RXR-mediated activation of the PBRU. J Biol Chem 276:7559–7567

    Article  PubMed  CAS  Google Scholar 

  • Kim KA, Park JY, Lee JS et al (2003a) Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res 26:631–637

    PubMed  CAS  Google Scholar 

  • Kim KA, Kim MJ, Park JY et al (2003b) Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. Drug Metab Dispos 31:1227–1234

    Article  PubMed  CAS  Google Scholar 

  • Kim KA, Park PW, Kim KR et al (2007) Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans. Br J Clin Pharmacol 63:339–345

    Article  PubMed  CAS  Google Scholar 

  • Kinonen T, Pasanen M, Gynther J et al (1995) Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouse CYP 2A5 and human CYP 2A6. Br J Pharmacol 116:2625–2630

    PubMed  CAS  Google Scholar 

  • Kirchheiner J, Brockmöller J (2005) Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 77:1–16

    Article  PubMed  CAS  Google Scholar 

  • Kirchheiner J, Fuhr U, Brockmöller J (2005) Pharmacogenetics-based therapeutic recommendations—ready for clinical practice? Nat Rev Drug Discov 4:639–647

    Article  PubMed  CAS  Google Scholar 

  • Kitada M, Kamataki T (1994) Cytochrome P450 in human fetal liver: significance and fetal-specific expression. Drug Metab Rev 26:305–323

    Article  PubMed  CAS  Google Scholar 

  • Kivistö KT, Bookjans G, Fromm MF et al (1996) Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br J Clin Pharmacol 42:387–389

    Article  PubMed  Google Scholar 

  • Kivistö KT, Niemi M, Fromm MF (2004) Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin Pharmacol 18:621–626

    Article  PubMed  CAS  Google Scholar 

  • Klees TM, Sheffels P, Dale O et al (2005) Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes. Drug Metab Dispos 33:303–311

    Article  PubMed  CAS  Google Scholar 

  • Kliewer SA, Moore JT, Wade L et al (1998) An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92:73–82

    Article  PubMed  CAS  Google Scholar 

  • Ko JW, Sukhova N, Thacker D et al (1997) Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 25:853–862

    PubMed  CAS  Google Scholar 

  • Ko JW, Desta Z, Soukhova NV et al (2000) In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. Br J Clin Pharmacol 49:343–351

    Article  PubMed  CAS  Google Scholar 

  • Kobayashi K, Yamamoto T, Chiba K et al (1995) The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol 40:481–485

    PubMed  CAS  Google Scholar 

  • Kobayashi K, Nakajima M, Chiba K et al (1998) Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. Br J Clin Pharmacol 45:361–368

    Article  PubMed  CAS  Google Scholar 

  • Kobayashi K, Abe S, Nakajima M et al (1999) Role of human CYP2B6 in S-mephobarbital N-demethylation. Drug Metab Dispos 27:1429–1433

    PubMed  CAS  Google Scholar 

  • Kobayashi K, Sueyoshi T, Inoue K et al (2003) Cytoplasmic accumulation of the nuclear receptor CAR by a tetratricopeptide repeat protein in HepG2 cells. Mol Pharmacol 64:1069–1075

    Article  PubMed  CAS  Google Scholar 

  • Kobayashi K, Yamanaka Y, Iwazaki N et al (2005) Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos 33:924–929

    Article  PubMed  CAS  Google Scholar 

  • Kodama S, Koike C, Negishi M et al (2004) Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes. Mol Cell Biol 24:7931–7940

    Article  PubMed  CAS  Google Scholar 

  • Kodama S, Moore R, Yamamoto Y et al (2007) Human nuclear pregnane X receptor cross-talk with CREB to repress cAMP activation of the glucose-6-phosphatase gene. Biochem J 407:373–381

    Article  PubMed  CAS  Google Scholar 

  • Koenigs LL, Peter RM, Thompson SJ et al (1997) Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab Dispos 25:1407–1415

    PubMed  CAS  Google Scholar 

  • Koike C, Moore R, Negishi M (2007) Extracellular signal-regulated kinase is an endogenous signal retaining the nuclear constitutive active/androstane receptor (CAR) in the cytoplasm of mouse primary hepatocytes. Mol Pharmacol 71:1217–1221

    Article  PubMed  CAS  Google Scholar 

  • Konishi H, Morita K, Minouchi T et al (1999) Preferential inhibition of CYP1A enzymes in hepatic microsomes by mexiletine. Eur J Drug Metab Pharmacokinet 24:149–153

    PubMed  CAS  Google Scholar 

  • Koop DR, Coon MJ (1986) (1986) Ethanol oxidation and toxicity: role of alcohol P-450 oxygenase. Alcohol Clin Exp Res 10(suppl 6):44S–49S

    Article  PubMed  CAS  Google Scholar 

  • Korjamo T, Honkakoski P, Toppinen MR et al (2005) Absorption properties and P-glycoprotein activity of modified Caco-2 cell lines. Eur J Pharm Sci 26:266–279

    Article  PubMed  CAS  Google Scholar 

  • Kostrubsky VE, Ramachandran V, Venkataramanan R et al (1999) The use of human hepatocyte cultures to study the induction of cytochrome P-450. Drug Metab Dispos 27:887–894

    PubMed  CAS  Google Scholar 

  • Koudriakova T, Iatsimirskaia E, Utkin I et al (1998) Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 26:552–561

    PubMed  CAS  Google Scholar 

  • Koyano S, Kurose K, Saito Y et al (2004) Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): one variant causes dramatic loss of both DNA binding activity and the transactivation of the CYP3A4 promoter/enhancer region. Drug Metab Dispos 32:149–154

    Article  PubMed  CAS  Google Scholar 

  • Kress S, Reichert J, Schwarz M (1998) Functional analysis of the human cytochrome P4501A1 (CYP1A1) gene enhancer. Eur J Biochem 258:803–812

    Article  PubMed  CAS  Google Scholar 

  • Kronbach T, Fischer V, Meyer UA (1988) Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 43:630–635

    PubMed  CAS  Google Scholar 

  • Kumar V, Rock DA, Warren CJ et al (2006) Enzyme source effects on CYP2C9 kinetics and inhibition. Drug Metab Dispos 34:1903–1908

    Article  PubMed  CAS  Google Scholar 

  • Kunze KL, Trager WF (1993) Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol 6:649–656

    Article  PubMed  CAS  Google Scholar 

  • Kunze KL, Wienkers LC, Thummel KE et al (1996) Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos 24:414–421

    PubMed  CAS  Google Scholar 

  • Kuypers DR, Claes K, Evenepoel P et al (2004) Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet 43:741–762

    Article  PubMed  CAS  Google Scholar 

  • Kyerematen GA, Morgan M, Warner G et al (1990) Metabolism of nicotine by hepatocytes. Biochem Pharmacol 40:1747–1756

    Article  PubMed  CAS  Google Scholar 

  • Laine K, Palovaara S, Tapanainen P et al (1999) Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy. Clin Pharmacol Ther 66:602–608

    PubMed  CAS  Google Scholar 

  • Lampe JW, Stepaniants SB, Mao M et al (2004) Signatures of environmental exposures using peripheral leukocyte gene expression: tobacco smoke. Cancer Epidemiol Biomarkers Prev 13:445–453

    PubMed  CAS  Google Scholar 

  • Landay RA, Gonzalez MA, Taylor JC (1978) Effect of phenobarbital on theophylline disposition. J Allergy Clin Immunol 62:27–29

    Article  PubMed  CAS  Google Scholar 

  • Landi MT, Sinha R, Lang NP et al (1999) Human cytochrome P4501A2. IARC Sci Publ 173–195

  • Lasser KE, Allen PD, Woolhandler SJ et al (2002) Timing of new black box warnings and withdrawals for prescription medications. JAMA 287:2215–2220

    Article  PubMed  Google Scholar 

  • Lau WC, Gurbel PA (2006) Antiplatelet drug resistance and drug–drug interactions: Role of cytochrome P450 3A4. Pharm Res 23:2691–2708

    Article  PubMed  CAS  Google Scholar 

  • Lavrijsen KL, Van Houdt JM, Van Dyck DM et al (1988) Is the metabolism of alfentanil subject to debrisoquine polymorphism? A study using human liver microsomes. Anesthesiology 69:535–540

    Article  PubMed  CAS  Google Scholar 

  • Lecamwasam DS, Franklin C, Turner P (1975) Effect of phenobarbitone on hepatic drug-metabolizing enzymes and urinary d-glucaric acid excretion in man. Br J Clin Pharmacol 2:257–262

    PubMed  CAS  Google Scholar 

  • LeCluyse EL (2001) Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 13:343–368

    Article  PubMed  CAS  Google Scholar 

  • Leemann T, Transon C, Dayer P (1993) Cytochrome P450 TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 52:29–34

    Article  PubMed  CAS  Google Scholar 

  • Lehmann JM, McKee DD, Watson MA et al (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102:1016–1023

    Article  PubMed  CAS  Google Scholar 

  • Lemaire G, Benod C, Nahoum V et al (2007) Discovery of a highly active ligand of human pregnane X receptor: a case study from pharmacophore modeling and virtual screening to “in vivo” biological activity. Mol Pharmacol 72(3):572–851

    Article  PubMed  CAS  Google Scholar 

  • Lerche-Langrand C, Toutain HJ (2000) Precision-cut liver slices: characteristics and use for in vitro pharmaco-toxicology. Toxicology 153:221–253

    Article  PubMed  CAS  Google Scholar 

  • Levine M, Sheppard I (1984) Biphasic interaction of phenytoin with warfarin. Clin Pharm 3:200–203

    PubMed  CAS  Google Scholar 

  • Lewis DF, Jacobs MN, Dickins M et al (2002) Quantitative structure–activity relationships for inducers of cytochromes P450 and nuclear receptor ligands involved in P450 regulation within the CYP1, CYP2, CYP3 and CYP4 families. Toxicology 176:51–57

    Article  PubMed  CAS  Google Scholar 

  • Lewis DF (2004) 57 Varieties: the human cytochromes P450. Pharmacogenomics 5:305–318

    Article  PubMed  CAS  Google Scholar 

  • Li AP, Gorycki PD, Hengstler JG et al (1999) Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel. Chem Biol Interact 121:117–123

    Article  PubMed  CAS  Google Scholar 

  • Li T, Chiang JY (2005) Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7 alpha-hydroxylase gene transcription. Am J Physiol Gastrointest Liver Physiol 288:G74–G84

    Article  PubMed  CAS  Google Scholar 

  • Li T, Chiang JY (2006) Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression. Drug Metab Dispos 34:756–764

    Article  PubMed  CAS  Google Scholar 

  • Li Y, Li NY, Sellers EM (1997) Comparison of CYP2A6 catalytic activity on coumarin 7-hydroxylation in human and monkey liver microsomes. Eur J Drug Metab Pharmacokinet 22:295–304

    PubMed  CAS  Google Scholar 

  • Li XQ, Björkman A, Andersson TB et al (2002) Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther 300:399–407

    Article  PubMed  CAS  Google Scholar 

  • Li XQ, Björkman A, Andersson TB et al (2003) Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 59:429–442

    Article  PubMed  CAS  Google Scholar 

  • Lieber CS (1999) Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968–1998)—a review. Alcohol Clin Exp Res 23:991–1007

    PubMed  CAS  Google Scholar 

  • Lieber CS (2004) The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role. Drug Metab Rev 36:511–529

    Article  PubMed  CAS  Google Scholar 

  • Lillibridge JH, Liang BH, Kerr BM et al (1998) Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 26:609–616

    PubMed  CAS  Google Scholar 

  • Lim ML, Min SS, Eron JJ et al (2004) Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr 36:1034–1040

    Article  PubMed  CAS  Google Scholar 

  • Lim PL, Tan W, Latchoumycandane C et al (2007) Molecular and functional characterization of drug-metabolizing enzymes and transporter expression in the novel spontaneously immortalized human hepatocyte line HC-04. Toxicol In Vitro 21:1390–1401

    Article  PubMed  CAS  Google Scholar 

  • Lin JH, Lu AY (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361–390

    Article  PubMed  CAS  Google Scholar 

  • Liu C, Russell RM, Wang XD (2003) Exposing ferrets to cigarette smoke and a pharmacological dose of beta-carotene supplementation enhance in vitro retinoic acid catabolism in lungs via induction of cytochrome P450 enzymes. J Nutr 133:173–179

    PubMed  CAS  Google Scholar 

  • Liu YT, Hao HP, Liu CX et al (2007) Drugs as CYP3A probes, inducers, and inhibitors. Drug Metab Rev 39:699–721

    Article  PubMed  CAS  Google Scholar 

  • Liu FJ, Song X, Yang D et al (2008) The far and distal enhancers in the CYP3A4 gene co-ordinate the proximal promoter in responding similarly to the pregnane X receptor but differentially to hepatocyte nuclear factor-4α. Biochem J 409:243–250

    Article  PubMed  CAS  Google Scholar 

  • Lo Piparo E, Koehler K et al (2006) Virtual screening for aryl hydrocarbon receptor binding prediction. J Med Chem 49:5702–5709

    Article  PubMed  CAS  Google Scholar 

  • Loboz KK, Gross AS, Williams KM et al (2006) Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther 80:75–84

    Article  PubMed  CAS  Google Scholar 

  • London SJ, Idle JR, Daly AK et al (1999) Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet 353:898–899

    Article  PubMed  CAS  Google Scholar 

  • Long M, Laier P, Vinggaard AM et al (2003) Effects of currently used pesticides in the AhR-CALUX assay: comparison between the human TV101L and the rat H4IIE cell line. Toxicology 194:77–93

    Article  PubMed  CAS  Google Scholar 

  • Lopez-Cortes LF, Ruiz-Valderas R, Viciana P et al (2002) Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 41:681–690

    Article  PubMed  CAS  Google Scholar 

  • Lucas D, Menez C, Girre C et al (1995) Decrease in cytochrome P4502E1 as assessed by the rate of chlorzoxazone hydroxylation in alcoholics during the withdrawal phase. Alcohol Clin Exp Res 19:362–366

    Article  PubMed  CAS  Google Scholar 

  • Luo G, Cunningham M, Kim S et al (2002) CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 30:795–804

    Article  PubMed  CAS  Google Scholar 

  • Luo G, Guenthner T, Gan LS et al (2004) CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development. Curr Drug Metab 5:483–505

    Article  PubMed  CAS  Google Scholar 

  • Ma Q (2001) Induction of CYP1A1. The AhR/DRE paradigm: transcription, receptor regulation, and expanding biological roles. Curr Drug Metab 2:149–164

    Article  PubMed  CAS  Google Scholar 

  • Ma Q, Lu AY (2007) CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies. Drug Metab Dispos 35:1009–1016

    Article  PubMed  CAS  Google Scholar 

  • Ma X, Idle JR, Krausz KW et al (2005) Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos 33:489–494

    Article  PubMed  CAS  Google Scholar 

  • Ma X, Shah Y, Cheung C et al (2007) The PREgnane X receptor gene-humanized mouse: a model for investigating drug–drug interactions mediated by cytochromes P450 3A. Drug Metab Dispos 35:194–200

    Article  PubMed  CAS  Google Scholar 

  • Madan A, Usuki E, Burton LA et al (2002) In vitro approaches for studying the inhibition of drug-metabolizing enzymes responsible for the metabolism of drugs. In: Rodrigues AD (ed) Drug–drug interactions: from basic pharmacokinetic concepts to marketing issues. Marcel-Dekker, London

    Google Scholar 

  • Madan A, Graham RA, Carroll KM et al (2003) Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31:421–431

    Article  PubMed  CAS  Google Scholar 

  • Mäenpää J, Juvonen R, Raunio H et al (1994) Metabolic interactions of methoxsalen and coumarin in humans and mice. Biochem Pharmacol 48(7):1363–1369

    Article  PubMed  Google Scholar 

  • Mäenpää J, Hall SD, Ring BJ et al (1998) Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone. Pharmacogenetics 8:137–155

    PubMed  Google Scholar 

  • Maglich JM, Parks DJ, Moore LB et al (2003) Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J Biol Chem 278(19):17277–17283

    Article  PubMed  CAS  Google Scholar 

  • Mäkinen J, Frank C, Jyrkkärinne J et al (2002) Modulation of mouse and human phenobarbital-responsive enhancer module by nuclear receptors. Mol Pharmacol 62(2):366–378

    Article  PubMed  Google Scholar 

  • Mäkinen J, Reinisalo M, Niemi K et al (2003) Dual action of oestrogens on the mouse constitutive androstane receptor. Biochem J 376:465–472

    Article  PubMed  Google Scholar 

  • Manno M, Rezzadore M, Grossi M et al (1996) Potentiation of occupational carbon tetrachloride toxicity by ethanol abuse. Hum Exp Toxicol 15:294–300

    PubMed  CAS  Google Scholar 

  • Martin H, Sarsat JP, de Waziers I et al (2003) Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices. Pharm Res 20:557–568

    Article  PubMed  CAS  Google Scholar 

  • Martin P, Riley R, Back DJ et al (2008) Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. Br J Pharmacol 153(4):805–819

    Article  PubMed  CAS  Google Scholar 

  • Maruyama M, Matsunaga T, Harada E et al (2007) Comparison of basal gene expression and induction of CYP3As in HepG2 and human fetal liver cells. Biol Pharm Bull 30(11):2091–2097

    Article  PubMed  CAS  Google Scholar 

  • Masuyama H, Suwaki N, Tateishi Y et al (2005) The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. Mol Endocrinol 19:1170–1180

    Article  PubMed  CAS  Google Scholar 

  • Matsunaga T, Maruyama M, Harada E et al (2004) Expression and induction of CYP3As in human fetal hepatocytes. Biochem Biophys Res Commun 318(2):428–434

    Article  PubMed  CAS  Google Scholar 

  • Mazze RI, Woodruff RE, Heerdt ME (1982) Isoniazid-induced enflurane defluorination in humans. Anesthesiology 57:5–8

    Article  PubMed  CAS  Google Scholar 

  • McCarver DG, Hines RN (2002) The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther 300:361–366

    Article  PubMed  CAS  Google Scholar 

  • McCune JS, Hawke RL, LeCluyse EL et al (2000) In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 68:356–366

    Article  PubMed  CAS  Google Scholar 

  • McDonnell WM, Scheiman JM, Traber PG (1992) Induction of cytochrome P450IA genes (CYP1A) by omeprazole in the human alimentary tract. Gastroenterology 103:1509–1516

    PubMed  CAS  Google Scholar 

  • McLellan RA, Drobitch RK, Monshouwer M et al (1996) Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. Drug Metab Dispos 24:1134–1138

    PubMed  CAS  Google Scholar 

  • Mekenyan OG, Veith GD, Call DJ et al (1996) A QSAR evaluation of Ah receptor binding of halogenated aromatic xenobiotics. Environ Health Perspect 104:1302–1310

    Article  PubMed  CAS  Google Scholar 

  • Messina ES, Tyndale RF, Sellers EM (1997) A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 282:1608–1614

    PubMed  CAS  Google Scholar 

  • Mihara K, Svensson US, Tybring G et al (1999) Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19. Fundam Clin Pharmacol 13:671–675

    PubMed  CAS  Google Scholar 

  • Miki Y, Suzuki T, Tazawa C et al (2005) Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues. Mol Cell Endocrinol 231:75–85

    Article  PubMed  CAS  Google Scholar 

  • Mildvan D, Yarrish R, Marshak A et al (2002) Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. J Acquir Immune Defic Syndr 29:471–477

    PubMed  CAS  Google Scholar 

  • Miller M, Cosgriff J, Kwong T et al (1984) Influence of phenytoin on theophylline clearance. Clin Pharmacol Ther 35:666–669

    PubMed  CAS  Google Scholar 

  • Mimura J, Ema M, Sogawa K et al (1999) Identification of a novel mechanism of regulation of Ah (dioxin) receptor function. Genes Dev 13:20–25

    Article  PubMed  CAS  Google Scholar 

  • Miners JO, Coulter S, Tukey RH et al (1996) Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen. Biochem Pharmacol 51:1003–1008

    Article  PubMed  CAS  Google Scholar 

  • Miners JO, Birkett DJ (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525–538

    Article  PubMed  CAS  Google Scholar 

  • Mollerup S, Ryberg D, Hewer A et al (1999) Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res 59:3317–3320

    PubMed  CAS  Google Scholar 

  • Moore LB, Parks DJ, Jones SA et al (2000) Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 275:15122–15127

    Article  PubMed  CAS  Google Scholar 

  • Moore LB, Maglich JM, McKee DD et al (2002) Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol Endocrinol 16:977–986

    Article  PubMed  CAS  Google Scholar 

  • Moriguchi T, Motohashi H, Hosoya T et al (2003) Distinct response to dioxin in an arylhydrocarbon receptor (AHR)-humanized mouse. Proc Natl Acad Sci USA 100:5652–5657

    Article  PubMed  CAS  Google Scholar 

  • Mortimer O, Persson K, Ladona MG et al (1990) Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1. Clin Pharmacol Ther 47:27–35

    PubMed  CAS  Google Scholar 

  • Mouly S, Lown KS, Kornhauser D et al (2002) Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 72:1–9

    Article  PubMed  CAS  Google Scholar 

  • Murk AJ, Legler J, Denison MS et al (1996) Chemical-activated luciferase gene expression (CALUX): a novel in vitro bioassay for Ah receptor active compounds in sediments and pore water. Fundam Appl Toxicol 33:149–160

    Article  PubMed  CAS  Google Scholar 

  • Nabuurs SB, Wagener M, de Vlieg J (2007) A flexible approach to induced fit docking. J Med Chem 50:6507–6518

    Article  PubMed  CAS  Google Scholar 

  • Nagy SR, Sanborn JR, Hammock BD et al (2002) Development of a green fluorescent protein-based cell bioassay for the rapid and inexpensive detection and characterization of Ah receptor agonists. Toxicol Sci 65:200–210

    Article  PubMed  CAS  Google Scholar 

  • Nakajima M, Yokoi T, Mizutani M et al (1994) Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev 3:413–421

    PubMed  CAS  Google Scholar 

  • Nakajima M, Yamamoto T, Nunoya K et al (1996a) Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 24:1212–1217

    PubMed  CAS  Google Scholar 

  • Nakajima M, Yamamoto T, Nunoya K et al (1996b) Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther 277:1010–1015

    PubMed  CAS  Google Scholar 

  • Nakajima M, Inoue T, Shimada N et al (1998) Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes. Drug Metab Dispos 26:261–266

    PubMed  CAS  Google Scholar 

  • Nakamura K, Moore R, Negishi M et al (2007) Nucar pregnane X receptor cross-talk with FoxA2 to mediate drug-induced regulation of lipid metabolism in fasting mouse liver. J Biol Chem 282:9768–9776

    Article  PubMed  CAS  Google Scholar 

  • Nebert DW, Dalton TP (2006) The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 6:947–960

    Article  PubMed  CAS  Google Scholar 

  • Nebert DW, Zhang G, Vesell ES (2008) From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev 40:187–224

    Article  PubMed  CAS  Google Scholar 

  • Nelson DR, Zeldin DC, Hoffman SM et al (2004) Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14:1–18

    Article  PubMed  CAS  Google Scholar 

  • Newton DJ, Wang RW, Lu AY (1995) Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154–158

    PubMed  CAS  Google Scholar 

  • Nguyen LP, Bradfield CA (2008) The search for endogenous activators of the aryl hydrocarbon receptor. Chem Res Toxicol 21:102–116

    Article  PubMed  CAS  Google Scholar 

  • Nielsen TL, Rasmussen BB, Flinois JP et al (1999) In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes. J Pharmacol Exp Ther 289:31–37

    PubMed  CAS  Google Scholar 

  • Niemi M, Backman JT, Neuvonen M et al (2000) Rifampin decreases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 68:495–500

    Article  PubMed  CAS  Google Scholar 

  • Niemi M, Backman JT, Neuvonen M et al (2001) Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther 69:400–406

    Article  PubMed  CAS  Google Scholar 

  • Niemi M, Leathart JB, Neuvonen M et al (2003a) Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther 74:380–387

    Article  PubMed  CAS  Google Scholar 

  • Niemi M, Backman JT, Fromm MF et al (2003b) Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 42:819–850

    Article  PubMed  CAS  Google Scholar 

  • Niemi M, Backman JT, Neuvonen PJ (2004) Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin Pharmacol Ther 76:239–249

    Article  PubMed  CAS  Google Scholar 

  • Nishimura M, Naito S, Yokoi T (2004) Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. Drug Metab Pharmacokinet 19:135–149

    Article  PubMed  CAS  Google Scholar 

  • Nishimura M, Yoshitsugu H, Yokoi T et al (2005) Evaluation of mRNA expression of human drug-metabolizing enzymes and transporters in chimeric mouse with humanized liver. Xenobiotica 35:877–890

    Article  PubMed  CAS  Google Scholar 

  • Nishizato Y, Ieiri I, Suzuki H et al (2003) Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73:554–565

    Article  PubMed  CAS  Google Scholar 

  • Niwa T, Shiraga T, Takagi A (2005) Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 28:1805–1808

    Article  PubMed  CAS  Google Scholar 

  • Nunoya K, Yokoi Y, Kimura K et al (1996) (+)-cis-3, 5-Dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502) as a novel substrate for cytochrome P450 2A6 in human liver microsomes. J Pharmacol Exp Ther 277:768–774

    PubMed  CAS  Google Scholar 

  • Obach RS, Walsky RL, Venkatakrishnan K et al (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug–drug interactions. J Pharmacol Exp Ther 316:336–348

    Article  PubMed  CAS  Google Scholar 

  • Oda Y, Furuichi K, Tanaka K et al (1995) Metabolism of a new local anesthetic, ropivacaine, by human hepatic cytochrome P450. Anesthesiology 82:214–220

    Article  PubMed  CAS  Google Scholar 

  • Oda Y, Hamaoka N, Hiroi T et al (2001) Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. Br J Clin Pharmacol 51:281–285

    Article  PubMed  CAS  Google Scholar 

  • Ogg MS, Williams JM, Tarbit M et al (1999) A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro. Xenobiotica 29:269–279

    Article  PubMed  CAS  Google Scholar 

  • Ogilvie BW, Zhang D, Li W et al (2006) Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug–drug interactions. Drug Metab Dispos 34:191–197

    Article  PubMed  CAS  Google Scholar 

  • Ogiso T, Iwaki M, Uno S (1995) Inhibition kinetics of theophylline metabolism by mexiletine and its metabolites. Biol Pharm Bull 18:75–81

    PubMed  CAS  Google Scholar 

  • Ohyama K, Nakajima M, Nakamura S et al (2000) A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos 28:1303–1310

    PubMed  CAS  Google Scholar 

  • Olesen OV, Linnet K (2001) Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol 41:823–832

    Article  PubMed  CAS  Google Scholar 

  • Oneta CM, Lieber CS, Li J et al (2002) Dynamics of cytochrome P4502E1 activity in man: induction by ethanol and disappearance during withdrawal phase. J Hepatol 36:47–52

    Article  PubMed  CAS  Google Scholar 

  • Ono S, Hatanaka T, Hotta H et al (1995) Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics 5:143–150

    Article  PubMed  CAS  Google Scholar 

  • Orans J, Teotico DG, Redinbo MR (2005) The nuclear xenobiotic receptor pregnane X receptor: recent insights and new challenges. Mol Endocrinol 19:2891–2900

    Article  PubMed  CAS  Google Scholar 

  • O’Reilly RA (1974) Interaction of sodium warfarin and rifampin. Studies in man. Ann Intern Med 81:337–340

    PubMed  CAS  Google Scholar 

  • O’Reilly RA, Trager WF, Motley CH et al (1980) Interaction of secobarbital with warfarin pseudoracemates. Clin Pharmacol Ther 28:187–195

    PubMed  CAS  Google Scholar 

  • Orlando R, Piccoli P, De Martin S et al (2004) Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. Clin Pharmacol Ther 75:80–88

    Article  PubMed  CAS  Google Scholar 

  • Orme M, Breckenridge A (1976) Enantiomers of warfarin and phenobarbital. N Engl J Med 295:1482–1483

    PubMed  CAS  Google Scholar 

  • Osabe M, Sugatani J, Takemura A et al (2008) Expression of CAR in SW480 and HepG2 cells during G1 is associated with cell proliferation. Biochem Biophys Res Commun 369:1027–1033

    Article  PubMed  CAS  Google Scholar 

  • O’Shea D, Kim RB, Wilkinson GR (1997) Modulation of CYP2E1 activity by isoniazid in rapid and slow N-acetylators. Br J Clin Pharmacol 43:99–103

    Article  PubMed  CAS  Google Scholar 

  • Otton SV, Inaba T, Kalow W (1984) Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. Life Sci 34:73–80

    Article  PubMed  CAS  Google Scholar 

  • Otton SV, Brinn RU, Gram LF (1988) In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver. Drug Metab Dispos 16:15–17

    PubMed  CAS  Google Scholar 

  • Ourlin JC, Lasserre F, Pineau T et al (2003) The small heterodimer partner interacts with the pregnane X receptor and represses its transcriptional activity. Mol Endocrinol 17:1693–1703

    Article  PubMed  CAS  Google Scholar 

  • Paine MF, Hart HL, Ludington SS et al (2006) The human intestinal cytochrome P450 “pie”. Drug Metab Dispos 34:880–886

    Article  PubMed  CAS  Google Scholar 

  • Paladino JA, Blumer NA, Maddox RR (1983) Effect of secobarbital on theophylline clearance. Ther Drug Monit 5:135–139

    Article  PubMed  CAS  Google Scholar 

  • Palovaara S, Pelkonen O, Uusitalo J et al (2003) Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther 74:326–333

    Article  PubMed  CAS  Google Scholar 

  • Park BK, Kitteringham NR, Pirmohamed M et al (1996) Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications. Br J Clin Pharmacol 41:477–491

    Article  PubMed  CAS  Google Scholar 

  • Park JY, Kim KA, Kang MH et al (2004) Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Ther 75:157–162

    Article  PubMed  CAS  Google Scholar 

  • Parker AC, Pritchard P, Preston T et al (1998) Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test. Br J Clin Pharmacol 45:176–178

    Article  PubMed  CAS  Google Scholar 

  • Parkinson A, Mudra DR, Johnson C et al (2004) The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199:193–209

    Article  PubMed  CAS  Google Scholar 

  • Pascussi JM, Gerbal-Chaloin S, Duret C et al (2008) The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. Annu Rev Pharmacol Toxicol 48:1–32

    Article  PubMed  CAS  Google Scholar 

  • Patki KC, Von Moltke LL, Greenblatt DJ (2003) In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos 31:938–944

    Article  PubMed  CAS  Google Scholar 

  • Pearce R, Greenway D, Parkinson A (1992) Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. Arch Biochem Biophys 298:211–225

    Article  PubMed  CAS  Google Scholar 

  • Pearce RE, Rodrigues AD, Goldstein JA et al (1996) Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 277:805–816

    PubMed  CAS  Google Scholar 

  • Pelkonen O, Sotaniemi EA, Ahokas JT (1985) Coumarin 7-hydroxylase activity in human liver microsomes. Properties of the enzyme and interspecies comparisons. Br J Clin Pharmacol 19:59–66

    PubMed  CAS  Google Scholar 

  • Pelkonen O, Mäenpää J, Taavitsainen P et al (1998) Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 28:1203–1253

    Article  PubMed  CAS  Google Scholar 

  • Pelkonen O, Rautio A, Raunio H et al (2000) CYP2A6: a human coumarin 7-hydroxylase. Toxicology 144:139–147

    Article  PubMed  CAS  Google Scholar 

  • Pelkonen O, Turpeinen M, Uusitalo J et al (2005) Prediction of drug metabolism and interactions on the basis of in vitro investigations. Basic Clin Pharmacol Toxicol 96:167–175

    Article  PubMed  CAS  Google Scholar 

  • Pelkonen O, Kapitulnik J, Gundert-Remy U et al (2008) Local kinetics and dynamics of xenobiotics. Crit Rev Toxicol, in press

  • Perrot N, Nalpas B, Yang CS et al (1989) Modulation of cytochrome P450 isozymes in human liver, by ethanol and drug intake. Eur J Clin Invest 19:549–555

    Article  PubMed  CAS  Google Scholar 

  • Persson KP, Ekehed S, Otter C et al (2006) Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome P450 induction potential of drugs in vivo in humans. Pharm Res 23:56–69

    Article  PubMed  CAS  Google Scholar 

  • Perucca E (2006) Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 61:246–255

    Article  PubMed  CAS  Google Scholar 

  • Perucca E, Grimaldi R, Frigo GM et al (1988) Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur J Clin Pharmacol 34:595–599

    Article  PubMed  CAS  Google Scholar 

  • Pfrunder A, Gutmann H, Beglinger C et al (2003) Gene expression of CYP3A4, ABC-transporters (MDR1 and MRP1-MRP5) and hPXR in three different human colon carcinoma cell lines. J Pharm Pharmacol 55:59–66

    Article  PubMed  CAS  Google Scholar 

  • Pinto AG, Wang YH, Chalasani N et al (2005) Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther 77:178–188

    Article  PubMed  CAS  Google Scholar 

  • Plant N (2007) The human cytochrome P450 sub-family: transcriptional regulation, inter-individual variation and interaction networks. Biochim Biophys Acta 1770:478–488

    PubMed  CAS  Google Scholar 

  • Pollock BG, Wylie M, Stack JA et al (1999) Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women. J Clin Pharmacol 39:936–940

    Article  PubMed  CAS  Google Scholar 

  • Poso A, Honkakoski P (2006) Ligand recognition by drug-activated nuclear receptors PXR and CAR: structural, site-directed mutagenesis and molecular modeling studies. Mini Rev Med Chem 6:937–947

    Article  PubMed  CAS  Google Scholar 

  • Projean D, Baune B, Farinotti R et al (2003) In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos 31:748–754

    Article  PubMed  CAS  Google Scholar 

  • Prueksaritanont T, Gorham LM, Ma B et al (1997) In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 25:1191–1199

    PubMed  CAS  Google Scholar 

  • Prueksaritanont T, Ma B, Yu N (2003) The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol 56:120–124

    Article  PubMed  CAS  Google Scholar 

  • Puurunen J, Pelkonen O (1979) Cimetidine inhibits microsomal drug metabolism in the rat. Eur J Pharmacol 55:335–336

    Article  PubMed  CAS  Google Scholar 

  • Rae JM, Soukhova NV, Flockhart DA et al (2002) Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Dispos 30:525–530

    Article  PubMed  CAS  Google Scholar 

  • Raffalli-Mathieu F, Glisovic T, Ben-David Y et al (2002) Heterogeneous nuclear ribonucleoprotein A1 and regulation of the xenobiotic-inducible gene Cyp2a5. Mol Pharmacol 61:795–799

    Article  PubMed  CAS  Google Scholar 

  • Ramírez J, Innocenti F, Schuetz EG et al (2004) CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos 32:930–936

    PubMed  Google Scholar 

  • Rasheed A, Hines RN, McCarver-May DG (1997) Variation in induction of human placental CYP2E1: possible role in susceptibility to fetal alcohol syndrome? Toxicol Appl Pharmacol 144:396–400

    Article  PubMed  CAS  Google Scholar 

  • Rasmussen BB, Maënpää J, Pelkonen O et al (1995) Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 39:151–159

    PubMed  CAS  Google Scholar 

  • Rasmussen BB, Brix TH, Kyvik KO et al (2002) The interindividual differences in the 3-demethylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics 12:473–478

    Article  PubMed  CAS  Google Scholar 

  • Raucy JL, Kraner JC, Lasker JM (1993) Bioactivation of halogenated hydrocarbons by cytochrome P4502E1. Crit Rev Toxicol 23:1–20

    Article  PubMed  CAS  Google Scholar 

  • Raucy JL, Schultz ED, Wester MR et al (1997) Human lymphocyte cytochrome P450 2E1, a putative marker for alcohol-mediated changes in hepatic chlorzoxazone activity. Drug Metab Dispos 25:1429–1435

    PubMed  CAS  Google Scholar 

  • Raucy JL, Schultz ED, Kearins MC et al (1999) CYP2E1 expression in human lymphocytes from various ethnic populations. Alcohol Clin Exp Res 23:1868–1874

    PubMed  CAS  Google Scholar 

  • Raunio H, Rautio A, Gullstén H et al (2001) Polymorphisms of CYP2A6 and its practical consequences. Br J Clin Pharmacol 52:357–363

    Article  PubMed  CAS  Google Scholar 

  • Reed GA, Peterson KS, Smith HJ et al (2005) A phase I study of indole-3-carbinol in women: tolerability and effects. Cancer Epidemiol Biomarkers Prev 14:1953–1960

    Article  PubMed  CAS  Google Scholar 

  • Relling MV, Aoyama T, Gonzalez FJ et al (1990) Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 252:442–447

    PubMed  CAS  Google Scholar 

  • Rencurel F, Foretz M, Kaufmann MR et al (2006) Stimulation of AMP-activated protein kinase is essential for the induction of drug metabolizing enzymes by phenobarbital in human and mouse liver. Mol Pharmacol 70:1925–1934

    Article  PubMed  CAS  Google Scholar 

  • Rencurel F, Stenhouse A, Hawley SA et al (2005) AMP-activated protein kinase mediates phenobarbital induction of CYP2B gene expression in hepatocytes and a newly derived human hepatoma cell line. J Biol Chem 280:4367–4373

    Article  PubMed  CAS  Google Scholar 

  • Rendic S, Sunjic V, Toso R et al (1979) Interaction of cimetidine with liver microsomes. Xenobiotica 9:555–564

    Article  PubMed  CAS  Google Scholar 

  • Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83–448

    Article  PubMed  CAS  Google Scholar 

  • Reschly EJ, Krasowski MD (2006) Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds. Curr Drug Metab 7:349–365

    Article  PubMed  CAS  Google Scholar 

  • Richter E, Breimer DD, Zilly W (1980) Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. Eur J Clin Pharmacol 17:197–202

    Article  PubMed  CAS  Google Scholar 

  • Richter T, Mürdter TE, Heinkele G et al (2004) Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 308:189–197

    Article  PubMed  CAS  Google Scholar 

  • Richter T, Schwab M, Eichelbaum M et al (2005) Inhibition of human CYP2B6 by N, N′, N″-triethylenethiophosphoramide is irreversible and mechanism-based. Biochem Pharmacol 69:517–524

    Article  PubMed  CAS  Google Scholar 

  • Ring BJ, Gillespie JS, Eckstein JA et al (2002) Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos 30:319–323

    Article  PubMed  CAS  Google Scholar 

  • Rivera SP, Saarikoski ST, Hankinson O (2002) Identification of a novel dioxin-inducible cytochrome P450. Mol Pharmacol 61:255–259

    Article  PubMed  CAS  Google Scholar 

  • Roberts EA, Johnson KC, Harper PA et al (1990) Characterization of the Ah receptor mediating aryl hydrocarbon hydroxylase induction in the human liver cell line Hep G2. Arch Biochem Biophys 276:442–450

    Article  PubMed  CAS  Google Scholar 

  • Robertson P Jr, Hellriegel ET, Arora S et al (2002) Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers. Clin Pharmacol Ther 71:46–56

    Article  PubMed  CAS  Google Scholar 

  • Rochat B, Morsman JM, Murray GI et al (2001) Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther 296:537–541

    PubMed  CAS  Google Scholar 

  • Rodrigues AD, Kukulka MJ, Roberts EM et al (1996) [O-methyl 14C]naproxen O-demethylase activity in human liver microsomes: evidence for the involvement of cytochrome P4501A2 and P4502C9/10. Drug Metab Dispos 24:126–136

    PubMed  CAS  Google Scholar 

  • Rodríguez-Antona C, Donato MT, Boobis A et al (2002) Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 32:505–520

    Article  PubMed  CAS  Google Scholar 

  • Rodriguez-Antona C, Niemi M, Backman JT et al (2007) Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J. doi:10.1038/sj.tpj.6500482

  • Rostami-Hodjegan A, Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140–148

    Article  PubMed  CAS  Google Scholar 

  • Rouleau N, Turcotte S, Mondou MH et al (2003) Development of a versatile platform for nuclear receptor screening using AlphaScreen. J Biomol Screen 8:191–197

    Article  PubMed  CAS  Google Scholar 

  • Roy P, Yu LJ, Crespi CL et al (1999a) Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 7:655–666

    Google Scholar 

  • Roy P, Tretyakov O, Wright J et al (1999b) Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer. Drug Metab Dispos 7:1309–1318

    Google Scholar 

  • Roymans D, Annaert P, Van Houdt J et al (2005) Expression and induction potential of cytochromes P450 in human cryopreserved hepatocytes. Drug Metab Dispos 33:1004–1016

    Article  PubMed  CAS  Google Scholar 

  • Rumack BH (2004) Acetaminophen misconceptions. Hepatology 40:10–15

    Article  PubMed  CAS  Google Scholar 

  • Saarikoski ST, Rivera SP, Hankinson O et al (2005) CYP2S1: a short review. Toxicol Appl Pharmacol 207:62–69

    Article  PubMed  CAS  Google Scholar 

  • Sachse C, Brockmoller J, Bauer S et al (1999) Functional significance of a C → A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445–449

    Article  PubMed  CAS  Google Scholar 

  • Sahi J, Milad MA, Zheng X et al (2003) Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor. J Pharmacol Exp Ther 306:1027–1034

    Article  PubMed  CAS  Google Scholar 

  • Sanderink GJ, Bournique B, Stevens J et al (1997) Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. J Pharmacol Exp Ther 282:1465–1472

    PubMed  CAS  Google Scholar 

  • Sarkar MA, Jackson BJ (1994) Theophylline N-demethylations as probes for P4501A1 and P4501A2. Drug Metab Dispos 22:827–834

    PubMed  CAS  Google Scholar 

  • Saussele T, Burk O, Blievernicht JK et al (2007) Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole. Clin Pharmacol Ther 82:265–274

    Article  PubMed  CAS  Google Scholar 

  • Schmider J, Greenblatt DJ, Fogelman SM et al (1997) Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1. Biopharm Drug Dispos 18:227–240

    Article  PubMed  CAS  Google Scholar 

  • Schmider J, von Moltke LL, Shader RI et al (1999) Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine. Drug Metab Rev 31:545–560

    Article  PubMed  CAS  Google Scholar 

  • Schmiedlin-Ren P, Thummel KE, Fisher JM et al (1997) Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1a, 25-dihydroxyvitamin D3. Mol Pharmacol 51:741–754

    PubMed  CAS  Google Scholar 

  • Schneck DW, Birmingham BK, Zalikowski JA et al (2004) The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75:455–463

    Article  PubMed  CAS  Google Scholar 

  • Schuetz JD, Beach DL, Guzelian PS (1994) Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 4:11–20

    Article  PubMed  CAS  Google Scholar 

  • Schuster D, Langer T (2005) The identification of ligand features essential for PXR activation by pharmacophore modeling. J Chem Inf Model 45:431–439

    Article  PubMed  CAS  Google Scholar 

  • Schuster D, Steindl TM, Langer T (2006) Predicting drug metabolism induction in silico. Curr Top Med Chem 6:1627–1640

    Article  PubMed  CAS  Google Scholar 

  • Scott EE, Halpert JR (2005) Structures of cytochrome P450 3A4. Trends Biochem Sci 30:5–7

    Article  PubMed  CAS  Google Scholar 

  • Seidel SD, Li V, Winter GM et al (2000) Ah receptor-based chemical screening bioassays: application and limitations for the detection of Ah receptor agonists. Toxicol Sci 55:107–115

    Article  PubMed  CAS  Google Scholar 

  • Seliskar M, Rozman D (2007) Mammalian cytochromes P450—importance of tissue specificity. Biochim Biophys Acta 1770:458–466

    PubMed  CAS  Google Scholar 

  • Sesardic D, Boobis AR, Edwards RJ et al (1988) A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 26:363–372

    PubMed  CAS  Google Scholar 

  • Sesardic D, Pasanen M, Pelkonen O et al (1990) Differential expression and regulation of members of the cytochrome P450IA gene subfamily in human tissues. Carcinogenesis 11:1183–1188

    Article  PubMed  CAS  Google Scholar 

  • Shadle CR, Lee Y, Majumdar AK et al (2004) Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 44:215–223

    Article  PubMed  CAS  Google Scholar 

  • Shan L, Vincent J, Brunzelle JS et al (2004) Structure of the murine constitutive androstane receptor complexed to androstenol: a molecular basis for inverse agonism. Mol Cell 16:907–917

    PubMed  CAS  Google Scholar 

  • Sherman W, Day T, Jacobson MP et al (2006) Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 49:534–553

    Article  PubMed  CAS  Google Scholar 

  • Shet MS, McPhaul M, Fisher CW et al (1997) Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. Drug Metab Dispos 25:1298–1303

    PubMed  CAS  Google Scholar 

  • Shimada T, Hayes CL, Yamazaki H et al (1996a) Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 56:2979–2984

    PubMed  CAS  Google Scholar 

  • Shimada T, Yamazaki H, Guengerich FP (1996b) Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica 26:395–403

    PubMed  CAS  Google Scholar 

  • Shitara Y, Hirano M, Sato H et al (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug–drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228–236

    Article  PubMed  CAS  Google Scholar 

  • Simonsson US, Jansson B, Hai TN et al (2003) Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Clin Pharmacol Ther 74:32–43

    Article  PubMed  CAS  Google Scholar 

  • Sinz M, Kim S, Zhu Z et al (2006) Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 7:375–388

    Article  PubMed  CAS  Google Scholar 

  • Slattery JT, Kalhorn TF, McDonald GB et al (1996) Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 14:1484–1494

    PubMed  CAS  Google Scholar 

  • Smith DA (2000) Induction and drug development. Eur J Pharm Sci 11:185–189

    Article  PubMed  CAS  Google Scholar 

  • Smith GB, Bend JR, Bedard LL et al (2003a) Biotransformation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in peripheral human lung microsomes. Drug Metab Dispos 31:1134–1141

    Article  PubMed  CAS  Google Scholar 

  • Smith G, Wolf CR, Deeni YY et al (2003b) Cutaneous expression of cytochrome P450 CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases. Lancet 361:1336–1343

    Article  PubMed  CAS  Google Scholar 

  • Smith G, Ibbotson SH, Comrie MM et al (2006) Regulation of cutaneous drug-metabolizing enzymes and cytoprotective gene expression by topical drugs in human skin in vivo. Br J Dermatol 155:275–281

    Article  PubMed  CAS  Google Scholar 

  • Smith DA, Dickins M, Fahmi OA et al (2007) The time to move cytochrome p450 induction into mainstream pharmacology is long overdue. Drug Metab Dispos 35:697–698

    Article  PubMed  CAS  Google Scholar 

  • Soars MG, Petullo DM, Eckstein JA et al (2004) An assessment of UDP-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab Dispos 32:140–148

    Article  PubMed  CAS  Google Scholar 

  • Soars MG, Grime K, Riley RJ (2006) Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5. Xenobiotica 36:287–299

    Article  PubMed  CAS  Google Scholar 

  • Solas C, Poizot-Martin I, Drogoul MP et al (2004) Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor. Br J Clin Pharmacol 57:436–440

    Article  PubMed  CAS  Google Scholar 

  • Song BJ, Veech RL, Park SS et al (1989) Induction of rat hepatic N-nitrosodimethylamine demethylase by acetone is due to protein stabilization. J Biol Chem 264:3568–3572

    PubMed  CAS  Google Scholar 

  • Sotaniemi EA, Rautio A, Backstrom M et al (1995) CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. Br J Clin Pharmacol 39:71–76

    PubMed  CAS  Google Scholar 

  • Soyama A, Hanioka N, Saito Y et al (2002) Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8 P404A. Pharmacol Toxicol 91:174–178

    Article  PubMed  CAS  Google Scholar 

  • Spaldin V, Madden S, Adams DA et al (1995) Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme-specific probe. Drug Metab Dispos 23:929–934

    PubMed  CAS  Google Scholar 

  • Squires EJ, Sueyoshi T, Negishi M (2004) Cytoplasmic localization of pregnane X receptor and ligand-dependent nuclear translocation in mouse liver. J Biol Chem 279: 49307–49314

    Article  PubMed  CAS  Google Scholar 

  • Staiger C, Schlicht F, Walter E et al (1983) Effect of single and multiple doses of sulphinpyrazone on antipyrine metabolism and urinary excretion of 6-beta-hydroxycortisol. Eur J Clin Pharmacol 25:797–801

    Article  PubMed  CAS  Google Scholar 

  • Stanley LA, Horsburgh BC, Ross J et al (2006) PXR and CAR: nuclear receptors which play a pivotal role in drug disposition and chemical toxicity. Drug Metab Rev 38:515–597

    Article  PubMed  CAS  Google Scholar 

  • Staudinger JL, Goodwin B, Jones SA et al (2001) The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA 98:3369–3374

    Article  PubMed  CAS  Google Scholar 

  • Stearns RA, Chakravarty PK, Chen R et al (1995) Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 23:207–215

    PubMed  CAS  Google Scholar 

  • Stevens JC, White RB, Hsu SH et al (1997) Human liver CYP2B6-catalyzed hydroxylation of RP 73401. J Pharmacol Exp Ther 282:1389–1395

    PubMed  CAS  Google Scholar 

  • Störmer E, von Moltke LL, Shader RI et al (2000) Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos 28:1168–1175

    PubMed  Google Scholar 

  • Sueyoshi T, Kawamoto T, Zelko I et al (1999) The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem 274:6043–6046

    Article  PubMed  CAS  Google Scholar 

  • Suino K, Peng L, Reynolds R et al (2004) The nuclear xenobiotic receptor CAR: structural determinants of constitutive activation and heterodimerization. Mol Cell 16:893–905

    PubMed  CAS  Google Scholar 

  • Sumida A, Fukuen S, Yamamoto I et al (2000) Quantitative analysis of constitutive and inducible CYPs mRNA expression in the HepG2 cell line using reverse transcription-competitive PCR. Biochem Biophys Res Commun 267:756–760

    Article  PubMed  CAS  Google Scholar 

  • Sun X, Li F, Wang YJ et al (2004) Development of an exonuclease protection mediated PCR bioassay for sensitive detection of Ah receptor agonists. Toxicol Sci 80:49–53

    Article  PubMed  CAS  Google Scholar 

  • Sustiva (2007) Electronic Medicines compendium (eMC). Available at http://emc.medicines.org.uk. Accessed 5 April 2008

  • Sutter TR, Tang YM, Hayes CL et al (1994) Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J Biol Chem 269:13092–13099

    PubMed  CAS  Google Scholar 

  • Svensson US, Ashton M, Trinh NH et al (1998) Artemisinin induces omeprazole metabolism in human beings. Clin Pharmacol Ther 64:160–167

    Article  PubMed  CAS  Google Scholar 

  • Svensson US, Ashton M (1999) Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol 48:528–535

    Article  PubMed  CAS  Google Scholar 

  • Taavitsainen P, Juvonen R, Pelkonen O (2001) In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans–2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metab Dispos 29:217–222

    PubMed  CAS  Google Scholar 

  • Takagi S, Nakajima M, Mohri T et al (2008) Post-transcriptional Regulation of Human Pregnane X Receptor by Micro-RNA Affects the Expression of Cytochrome P450 3A4. J Biol Chem 283:9674–9680

    Article  PubMed  CAS  Google Scholar 

  • Takahashi T, Lasker JM, Rosman AS et al (1993) Induction of cytochrome P-4502E1 in the human liver by ethanol is caused by a corresponding increase in encoding messenger RNA. Hepatology 17:236–245

    PubMed  CAS  Google Scholar 

  • Tang C, Lin JH, Lu AY (2005) Metabolism-based drug–drug interactions: what determines individual variability in cytochrome P450 induction? Drug Metab Dispos 33:603–613

    Article  PubMed  CAS  Google Scholar 

  • Tarrus E, Cami J, Roberts DJ et al (1987) Accumulation of caffeine in healthy volunteers treated with furafylline. Br J Clin Pharmacol 23:9–18

    PubMed  CAS  Google Scholar 

  • Tassaneeyakul W, Mohamed Z, Birkett DJ et al (1992) Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics 2:173–183

    Article  PubMed  CAS  Google Scholar 

  • Tassaneeyakul W, Birkett DJ, Veronese ME et al (1993a) Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401–407

    PubMed  CAS  Google Scholar 

  • Tassaneeyakul W, Veronese ME, Birkett DJ et al (1993b) Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochem Pharmacol 46:1975–1981

    Article  PubMed  CAS  Google Scholar 

  • Tassaneeyakul W, Guo LQ, Fukuda K et al (2000) Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch Biochem Biophys 378:356–363

    Article  PubMed  CAS  Google Scholar 

  • Tateishi T, Krivoruk Y, Ueng YF et al (1996) Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg 82:167–172

    Article  PubMed  CAS  Google Scholar 

  • Tateno C, Yoshizane Y, Saito N et al (2004) Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165:901–912

    PubMed  CAS  Google Scholar 

  • Thum T, Erpenbeck VJ, Moeller J et al (2006) Expression of xenobiotic metabolizing enzymes in different lung compartments of smokers and nonsmokers. Environ Health Perspect 114:1655–1661

    PubMed  CAS  Google Scholar 

  • Timsit YE, Negishi M (2007) CAR and PXR: the xenobiotic-sensing receptors. Steroids 72:231–246

    Article  PubMed  CAS  Google Scholar 

  • Tirona RG, Lee W, Leake BF et al (2003) The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 9:220–224

    Article  PubMed  CAS  Google Scholar 

  • Tjia JF, Colbert J, Back DJ (1996) Theophylline metabolism in human liver microsomes: inhibition studies. J Pharmacol Exp Ther 276:912–917

    PubMed  CAS  Google Scholar 

  • Tornheim K (1994) Kinetic applications using high substrate and competitive inhibitor concentrations to determine Ki or Km. Anal Biochem 221:53–56

    Article  PubMed  CAS  Google Scholar 

  • Totah RA, Rettie AE (2005) Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 77:341–352

    Article  PubMed  CAS  Google Scholar 

  • Tracy TS, Marra C, Wrighton SA et al (1996) Studies of flurbiprofen 4′-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9. Biochem Pharmacol 52:1305–1309

    Article  PubMed  CAS  Google Scholar 

  • Tracy TS, Marra C, Wrighton SA et al (1997) Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol 52:293–298

    Article  PubMed  CAS  Google Scholar 

  • Trubetskoy O, Marks B, Zielinski T et al (2005) A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line. AAPS J 7:E6–E13

    Article  PubMed  Google Scholar 

  • Tsutsumi M, Lasker JM, Shimizu M et al (1989) The intralobular distribution of ethanol-inducible P450IIE1 in rat and human liver. Hepatology 10:437–446

    Article  PubMed  CAS  Google Scholar 

  • Tsyrlov IB, Goldfarb IS, Gelboin HV (1993) Enzyme-kinetic and immunochemical characteristics of mouse cDNA-expressed, microsomal, and purified CYP1A1 and CYP1A2. Arch Biochem Biophys 307:259–266

    Article  PubMed  CAS  Google Scholar 

  • Tucker GT (1992) The rational selection of drug interaction studies: implications of recent advances in drug metabolism. Int J Clin Pharmacol Ther Toxicol 30:550–553

    PubMed  CAS  Google Scholar 

  • Tucker GT, Houston JB, Huang SM (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential–towards a consensus. Br J Clin Pharmacol 52:107–117

    Article  PubMed  CAS  Google Scholar 

  • Tugnait M, Hawes EM, McKay G et al (1999) Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine. Chem Biol Interact 118:171–189

    Article  PubMed  CAS  Google Scholar 

  • Turpeinen M, Nieminen R, Juntunen T et al (2004) Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab Dispos 32:626–631

    Article  PubMed  CAS  Google Scholar 

  • Turpeinen M, Uusitalo J, Jalonen J et al (2005a) Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur J Pharm Sci 24:123–132

    Article  PubMed  CAS  Google Scholar 

  • Turpeinen M, Tolonen A, Uusitalo J et al (2005b) Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther 77:553–559

    Article  PubMed  CAS  Google Scholar 

  • Turpeinen M, Raunio H, Pelkonen O (2006) The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico. Curr Drug Metab 7:705–714

    Article  PubMed  CAS  Google Scholar 

  • Udall JA (1975) Clinical implications of warfarin interactions with five sedatives. Am J Cardiol 35:67–71

    Article  PubMed  CAS  Google Scholar 

  • Ung CY, Li H, Yap CW et al (2007) In silico prediction of pregnane X receptor activators by machine learning approaches. Mol Pharmacol 71:158–168

    Article  PubMed  CAS  Google Scholar 

  • Valero F, de la Torre R, Segura J (1991) Selective in-vitro inhibition of hepatic oxidative metabolism by quinolones: 7-ethoxyresorufin and caffeine as model substrates. J Pharm Pharmacol 43:17–21

    PubMed  CAS  Google Scholar 

  • van Duijnhoven EM, Boots JM, Christiaans MH et al (2003) Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int 16:721–725

    PubMed  Google Scholar 

  • van Giersbergen PL, Gnerre C, Treiber A et al (2002a) Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor. Eur J Pharmacol 450:115–121

    Article  PubMed  Google Scholar 

  • van Giersbergen PL, Treiber A, Clozel M et al (2002b) In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. Clin Pharmacol Ther 71:253–262

    Article  PubMed  Google Scholar 

  • van Leeuwen DM, van Agen E, Gottschalk RW et al (2007) Cigarette smoke-induced differential gene expression in blood cells from monozygotic twin pairs. Carcinogenesis 28:691–697

    Article  PubMed  Google Scholar 

  • Vedani A, Dobler M, Lill MA (2006) The challenge of predicting drug toxicity in silico. Basic Clin Pharmacol Toxicol 99:195–208

    Article  PubMed  CAS  Google Scholar 

  • Vermeir M, Annaert P, Mamidi RN et al (2005) Cell-based models to study hepatic drug metabolism and enzyme induction in humans. Expert Opin Drug Metab Toxicol 1:75–90

    Article  PubMed  CAS  Google Scholar 

  • Veronese ME, Mackenzie PI, Doecke CJ et al (1991) Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 175:1112–1118

    Article  PubMed  CAS  Google Scholar 

  • Vesell ES, Page JG (1969) Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man. J Clin Invest 48:2202–2209

    Article  PubMed  CAS  Google Scholar 

  • Vickers AE, Sinclair JR, Zollinger M et al (1999) Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug–drug interactions. Drug Metab Dispos 27:1029–1038

    PubMed  CAS  Google Scholar 

  • Vignati LA, Bogni A, Grossi P et al (2004) A human and mouse pregnane X receptor reporter gene assay in combination with cytotoxicity measurements as a tool to evaluate species-specific CYP3A induction. Toxicology 199:23–33

    Article  PubMed  CAS  Google Scholar 

  • Villikka K, Kivisto KT, Neuvonen PJ (1998) The effect of dexamethasone on the pharmacokinetics of triazolam. Pharmacol Toxicol 83:135–138

    PubMed  CAS  Google Scholar 

  • Villikka K, Varis T, Backman JT et al (2001) Effect of methylprednisolone on CYP3A4-mediated drug metabolism in vivo. Eur J Clin Pharmacol 57:457–460

    Article  PubMed  CAS  Google Scholar 

  • von Moltke LL, Greenblatt DJ, Harmatz JS et al (1993) Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 47:268–276

    Article  Google Scholar 

  • von Moltke LL, Greenblatt DJ, Schmider J et al (1996a) Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 36:783–791

    Google Scholar 

  • von Moltke LL, Greenblatt DJ, Harmatz JS et al (1996b) Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370–379

    Google Scholar 

  • von Moltke LL, Greenblatt DJ, Duan SX et al (1998a) Inhibition of desipramine hydroxylation (Cytochrome P450–2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharm Sci 87:1184–1189

    Article  Google Scholar 

  • von Moltke LL, Greenblatt DJ, Schmider J et al (1998b) In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 55:113–122

    Article  Google Scholar 

  • von Richter O, Burk O, Fromm MF et al (2004) Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 75:172–183

    Article  CAS  Google Scholar 

  • Wacher VJ, Wu CY, Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129–134

    Article  PubMed  CAS  Google Scholar 

  • Waller CL, McKinney JD (1992) Comparative molecular field analysis of polyhalogenated dibenzo-p-dioxins, dibenzofurans, and biphenyls. J Med Chem 35:3660–3666

    Article  PubMed  CAS  Google Scholar 

  • Wallin H, Skipper PL, Tannenbaum SR et al (1995) Altered aromatic amine metabolism in epileptic patients treated with phenobarbital. Cancer Epidemiol Biomarkers Prev 4:771–773

    PubMed  CAS  Google Scholar 

  • Walsky RL, Obach RS (2004) Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647–660

    Article  PubMed  CAS  Google Scholar 

  • Walsky RL, Gaman EA, Obach RS (2005a) Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 45:68–78

    Article  PubMed  CAS  Google Scholar 

  • Walsky RL, Obach RS, Gaman EA et al (2005b) Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab Dispos 33:413–418

    Article  PubMed  CAS  Google Scholar 

  • Wang RW, Kari PH, Lu AY et al (1991) Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 290:355–361

    Article  PubMed  CAS  Google Scholar 

  • Wang RW, Newton DJ, Scheri TD et al (1997) Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis. Drug Metab Dispos 25:502–507

    CAS  Google Scholar 

  • Wang JS, Backman JT, Taavitsainen P et al (2000a) Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos 28:959–965

    PubMed  CAS  Google Scholar 

  • Wang RW, Newton DJ, Liu N et al (2000b) Human cytochrome P-450 3A4: in vitro drug–drug interaction patterns are substrate-dependent. Drug Metab Dispos 28:360–366

    PubMed  CAS  Google Scholar 

  • Wang JS, Neuvonen M, Wen X et al (2002) Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos 30:1352–1356

    Article  PubMed  Google Scholar 

  • Wang LS, Zhou G, Zhu B et al (2004a) St John’s wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 75:191–197

    Article  PubMed  CAS  Google Scholar 

  • Wang LS, Zhu B, Abd El-Aty AM et al (2004b) The influence of St John’s Wort on CYP2C19 activity with respect to genotype. J Clin Pharmacol 44:577–581

    Article  PubMed  CAS  Google Scholar 

  • Wang YH, Jones DR, Hall SD (2005) Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos 33:664–671

    Article  PubMed  CAS  Google Scholar 

  • Wang K, Mendy AJ, Dai G et al (2006) Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci 92:51–60

    Article  PubMed  CAS  Google Scholar 

  • Ward BA, Gorski JC, Jones DR et al (2003) The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306:287–300

    Article  PubMed  CAS  Google Scholar 

  • Warrington JS, Shader RI, von Moltke LL et al (2000) In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos 28:392–397

    PubMed  CAS  Google Scholar 

  • Watkins PB, Murray SA, Winkelman LG et al (1989) Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J Clin Invest 83:688–697

    Article  PubMed  CAS  Google Scholar 

  • Watkins RE, Wisely GB, Moore LB et al (2001) The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 292:2329–2333

    Article  PubMed  CAS  Google Scholar 

  • Waxman DJ, Lapenson DP, Aoyama T et al (1991) Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys 290:160–166

    Article  PubMed  CAS  Google Scholar 

  • Weber C, Banken L, Birnboeck H et al (1999) Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 39:847–854

    Article  PubMed  CAS  Google Scholar 

  • Wei C, Caccavale RJ, Weyand EH et al (2002) Induction of CYP1A1 and CYP1A2 expressions by prototypic and atypical inducers in the human lung. Cancer Lett 178:25–36

    Article  PubMed  CAS  Google Scholar 

  • Wen X, Wang JS, Backman JT et al (2002) Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos 30:631–635

    Article  PubMed  CAS  Google Scholar 

  • Westerink WM, Schoonen WG (2007) Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol In Vitro 21:1581–1591

    Article  PubMed  CAS  Google Scholar 

  • Westlind-Johnsson A, Malmebo S, Johansson A et al (2003) Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31:755–761

    Article  PubMed  CAS  Google Scholar 

  • Whyte JJ, Schmitt CJ, Tillitt DE (2004) The H4IIE cell bioassay as an indicator of dioxin-like chemicals in wildlife and the environment. Crit Rev Toxicol 34:1–83

    Article  PubMed  CAS  Google Scholar 

  • Wienkers LC, Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825–833

    Article  PubMed  CAS  Google Scholar 

  • Wietholtz H, Zysset T, Kreiten K et al (1989) Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism. Eur J Clin Pharmacol 36:401–406

    Article  PubMed  CAS  Google Scholar 

  • Wild MJ, McKillop D, Butters CJ (1999) Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan. Xenobiotica 29:847–857

    Article  PubMed  CAS  Google Scholar 

  • Williamson KM, Patterson JH, McQueen RH et al (1998) Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 63:316–323

    Article  PubMed  CAS  Google Scholar 

  • Williams JA, Ring BJ, Cantrell VE et al (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30:883–891

    Article  PubMed  CAS  Google Scholar 

  • Windshügel B, Jyrkkärinne J, Vanamo J et al (2007) Comparison of homology models and X-ray structures of the nuclear receptor CAR: assessing the structural basis of constitutive activity. J Mol Graph Model 25:644–657

    Article  PubMed  CAS  Google Scholar 

  • Wing LM, Miners JO, Lillywhite KJ (1985) Verapamil disposition—effects of sulphinpyrazone and cimetidine. Br J Clin Pharmacol 19:385–391

    PubMed  CAS  Google Scholar 

  • Wójcikowski J, Maurel P, Daniel W (2006) Characterization of human cytochrome p450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine. Drug Metab Dispos 34:471–476

    PubMed  Google Scholar 

  • Wrighton SA, Brian WR, Sari MA et al (1990) Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 38:207–213

    PubMed  CAS  Google Scholar 

  • Wu CY, Benet LZ, Hebert MF et al (1995) Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 58:492–497

    Article  PubMed  CAS  Google Scholar 

  • Xiao L, Cui X, Madison V et al (2002) Insights from a three-dimensional model into ligand binding to constitutive active receptor. Drug Metab Dispos 30:951–956

    Article  PubMed  CAS  Google Scholar 

  • Xie W, Barwick JL, Downes M et al (2000) Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406:435–439

    Article  PubMed  CAS  Google Scholar 

  • Xie W, Radominska-Pandya A, Shi Y et al (2001) An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci USA 98:3375–3380

    Article  PubMed  CAS  Google Scholar 

  • Xu RX, Lambert MH, Wisely BB et al (2004) A structural basis for constitutive activity in the human CAR/RXRalpha heterodimer. Mol Cell 16:919–928

    Article  PubMed  CAS  Google Scholar 

  • Xue Y, Moore LB, Orans J, Peng L, Bencharit S, Kliewer SA, Redinbo MR (2007) Crystal structure of the pregnane X receptor-estradiol complex provides insights into endobiotic recognition. Mol Endocrinol 21:1028–1038

    Article  PubMed  CAS  Google Scholar 

  • Yamanaka H, Nakajima M, Fukami T et al (2005) CYP2A6 and CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. Drug Metab Dispos 33:1811–1818

    PubMed  CAS  Google Scholar 

  • Yamano S, Tatsuno J, Gonzalez FJ (1990) The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29:1322–1329

    Article  PubMed  CAS  Google Scholar 

  • Yamazaki H, Hiroki S, Urano T et al (1996) Effects of roxithromycin, erythromycin and troleandomycin on their N-demethylation by rat and human cytochrome P450 enzymes. Xenobiotica 26:1143–1153

    Article  PubMed  CAS  Google Scholar 

  • Yamazaki H, Inoue K, Chiba K et al (1998) Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol 56:243–251

    Article  PubMed  CAS  Google Scholar 

  • Yamazaki H, Shimada T (1998) Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab Dispos 26:1053–1057

    PubMed  CAS  Google Scholar 

  • Yanagihara Y, Kariya S, Ohtani M et al (2001) Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 29:887–890

    PubMed  CAS  Google Scholar 

  • Yao D, Ding S, Burchell B et al (2000) Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance. J Pharmacol Exp Ther 294:387–395

    PubMed  CAS  Google Scholar 

  • Yasar U, Tybring G, Hidestrand M et al (2001) Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 29:1051–1056

    PubMed  CAS  Google Scholar 

  • Yasumori T, Li QH, Yamazoe Y et al (1994) Lack of low Km diazepam N-demethylase in livers of poor metabolizers for S-mephenytoin 4′-hydroxylation. Pharmacogenetics 4:323–331

    Article  PubMed  CAS  Google Scholar 

  • Yeh RF, Gaver VE, Patterson KB et al (2006) Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 42:52–60

    PubMed  CAS  Google Scholar 

  • Yeo KR, Yeo WW (2001) Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br J Clin Pharmacol 51:461–470

    Article  PubMed  CAS  Google Scholar 

  • Yoshida N, Oda Y, Nishi S et al (1993) Effect of barbiturate therapy on phenytoin pharmacokinetics. Crit Care Med 21:1514–1522

    Article  PubMed  CAS  Google Scholar 

  • Yoshinari K, Kobayashi K, Moore R et al (2003) Identification of the nuclear receptor CAR:HSP90 complex in mouse liver and recruitment of protein phosphatase 2A in response to phenobarbital. FEBS Lett 548:17–20

    Article  PubMed  CAS  Google Scholar 

  • You F, Zhou YF, Zhang XE et al (2006) Cell-free bioassay for measurement of dioxins based on fluorescence enhancement of fluorescein isothiocyanate-labeled DNA probe. Anal Chem 78:7138–7144

    Article  PubMed  CAS  Google Scholar 

  • Yuan R, Parmelee T, Balian JD et al (1999) In vitro metabolic interaction studies: experience of the Food and Drug Administration. Clin Pharmacol Ther 66:9–15

    Article  PubMed  CAS  Google Scholar 

  • Yuan R, Madani S, Wei XX et al (2002) Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30:1311–1319

    Article  PubMed  CAS  Google Scholar 

  • Yueh MF, Kawahara M, Raucy J (2005) Cell-based high-throughput bioassays to assess induction and inhibition of CYP1A enzymes. Toxicol In Vitro 19:275–287

    Article  PubMed  CAS  Google Scholar 

  • Zand R, Nelson SD, Slattery JT et al (1993) Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clin Pharmacol Ther 54:142–149

    PubMed  CAS  Google Scholar 

  • Zanger UM, Raimundo S, Eichelbaum M (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369:23–37

    Article  PubMed  CAS  Google Scholar 

  • Zanger UM, Klein K, Saussele T et al (2007) Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 8:743–759

    Article  PubMed  CAS  Google Scholar 

  • Zelko I, Sueyoshi T, Kawamoto T et al (2001) The peptide near the C terminus regulates receptor CAR nuclear translocation induced by xenochemicals in mouse liver. Mol Cell Biol 21:2838–2846

    Article  PubMed  CAS  Google Scholar 

  • Zhang L, Fitzloff JF, Engel LC et al (2001a) Species difference in stereoselective involvement of CYP3A in the mono-N-dealkylation of disopyramide. Xenobiotica 31:73–83

    Article  PubMed  CAS  Google Scholar 

  • Zhang W, Kilicarslan T, Tyndale RF et al (2001b) Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab Dispos 29:897–902

    PubMed  CAS  Google Scholar 

  • Zhang ZY, Pelletier RD, Wong YN et al (2006) Preferential inducibility of CYP1A1 and CYP1A2 by TCDD: differential regulation in primary human hepatocytes versus transformed human cells. Biochem Biophys Res Commun 34:399–407

    Article  CAS  Google Scholar 

  • Zhang H, Cui D, Wang B et al (2007) Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet 46:133–157

    Article  PubMed  CAS  Google Scholar 

  • Zhou S, Chan E, Pan SQ et al (2004) Pharmacokinetic interactions of drugs with St John’s wort. J Psychopharmacol 18:262–276

    Article  PubMed  CAS  Google Scholar 

  • Zhou C, Assem M, Tay JC et al (2006) Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest 116:1703–1712

    Article  PubMed  CAS  Google Scholar 

  • Zhu Z, Kim S, Chen T et al (2004) Correlation of high-throughput pregnane X receptor (PXR) transactivation and binding assays. J Biomol Screen 9:533–540

    Article  PubMed  CAS  Google Scholar 

  • Zhu M, Zhao W, Jimenez H et al (2005) Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos 33:500–507

    Article  PubMed  CAS  Google Scholar 

  • Zilly W, Breimer DD, Richter E (1975) Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. Eur J Clin Pharmacol 9:219–227

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors wish to thank the following sources for support to their research: The Academy of Finland, the Finnish Funding Agency for Technological Research and Innovation (TEKES), The EU COST Programme (COST B15 and COST B25).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Olavi Pelkonen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pelkonen, O., Turpeinen, M., Hakkola, J. et al. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 82, 667–715 (2008). https://doi.org/10.1007/s00204-008-0332-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00204-008-0332-8

Keywords

Navigation